2.1: Clinical characteristics and outcome of pulmonary hypertension among admitted heart failure patients
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Departments of Medicine and Chemical Pathology, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria

Heart failure (HF) and pulmonary hypertension (PHT) are common syndromes with significant morbidity and mortality globally. However, knowledge gap exists in sub-Saharan Africa regarding the impact of one over the other on morbidity and mortality. The present study, which was part of a larger study on HF, aimed at assessing the clinical characteristics and in-hospital outcome of PHT among HF patients admitted to a tertiary health center in Kano, Nigeria. The study was cross sectional in design, carried out in the medical wards of Aminu Kano Teaching Hospital, Kano, Nigeria. Patients admitted with HF were serially recruited and studied after obtaining informed consent. All patients were clinically evaluated, and had baseline investigations including electrocardiogram and echocardiogram (echo), while some of them had assay for *N*-terminal pro-B type natriuretic peptide (NT-BNP). PHT was defined as the presence of mean pulmonary artery pressure (mPAP) of ≥25 mmHg, assessed using continuous wave Doppler echo and Chemla formula. A total of 90 patients were studied, but the results presented here are for the 80 patients who had complete data. Fifty-three patients (66.25%) (Group 1) were found to have PHT while the remaining 27 (33.75%) had normal mPAP (Group 2). When the two groups were compared, mPAP for Group 1 was 38.31±12.23 mmHg while that for Group 2 was 16.39±5.48 mmHg (P\<0.001). Two patients in Group 1 and 1 patient in Group 2 were smokers. In addition, Group 1 as compared with Group 2 patients had significantly lower left ventricular ejection fraction, and larger left atrium and left ventricle (P\<0.05). NT-BNP was assessed in only 37 patients and the concentrations were found to be very high; 26 of them in Group 1 (14, 408±11,449) and 11 in Group 2 (12,266±11,497) (P=0.607). Twelve patients had atrial fibrillation, 8 of them in Group 1 and 4 in Group 2. The in-hospital mortality in Group 1 (8 patients=15.09%) was similar to that for Group 2 (4 patients=14.82%) (P=0.626); higher among females than males (8 versus 4 patients, respectively). The chance of discharge from hospital admission or in-hospital mortality was significantly influenced by the diagnosis of cardiogenic shock (odds ratio=0.069; 95% confidence interval=0.017-0.286; P\<0.001). The most common cause of HF was hypertensive heart disease seen in 28 patients, 13 of them in Group 1. Fifteen patients had peripartum cardiomyopathy; 13 of them were in Group 1. These were followed by dilated cardiomyopathy in 13 patients, 9 of them in Group 1; rheumatic heart disease in 8 patients, 7 of them in Group 1; ischemic heart disease in 6 patients, all of them in Group 1; corpulmonale in 5 patients, all in Group 1; and effusive pericarditis in 4 patients, all of them in Group 2. PHT is common in admitted HF patients, and is associated with worse parameters for morbidity. However, its influence on in-hospital mortality was not apparent. A follow-up study is needed to assess it effect on long-term mortality.

2.2: Heart rate recovery after 6-minute walk test in patients with pulmonary arterial hypertension

Minai OA and Gudavalli R

Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA

Attenuated heart rate recovery (HRR) after exercise testing is associated with increased mortality. The purpose of this study was to evaluate early HRR after 6-minute walk test (6-MWT) and the association between abnormal HRR and prognostic markers (WHO class, RV function, 6MWD etc.) in patients with idiopathic pulmonary arterial hypertension. Heart rate at 1-minute post 6MWT was collected routinely at our institute from August 2009. Demographic, clinical, hemodynamic, pulmonary function test and 6-MWT variables were collected in patients who had idiopathic pulmonary arterial hypertension and had a 6-MWT from August 2009 to March 2010. HRR1 was defined as the difference in the heart rate at the end of 6-MWT and at 1 minute after completion of the 6-MWT. A total of 1,444 patients underwent 6-MWT from August 2009 to March 2010. Of these, 75 patients had a diagnosis of PAH (Group 1.1 and 1.2) and were included in the final analysis. In our cohort of PAH patients, the mean age was 49.13 years, mean mPAP was 52.25 mmHg, mean plasma BNP was 177.1 pg/ml, mean eRVSP based on transthoracic echocardiogram (TTE) was 80.69 mmHg, mean 6-MWT was 440.6 meters, mean HRR1 was 21.29 bpm. HRR1 had a significant negative correlation with age (r= -0.37), RVSP (r= -0.30), and BNP levels (r= -0.61). HRR1 had a significant positive correlation with DLCO (r=0.34) and 6MWD (r=0.58). HRR1 was significantly lower in patients with WHO Class III/IV symptoms, elevated BNP levels, and moderate to severe RV dysfunction on TTE. Patients with a lower HRR1 (≤15) had a higher risk of hospitalization. HRR1 after 6-MWT correlates with several prognostic markers in PAH (Group 1.1 and 1.2) patients. HRR1 after 6-MWT was significantly lower in patients with WHO class III/IV symptoms, moderate to severe RV dysfunction on TTE, and elevated serum BNP levels.

2.3: Does high altitude protect against irreversible pulmonary hypertension?

Heath A, von Alvensleben I, Graham B, Tuder R, Brockman C, and Perez E. Kardiozentrum

Fundacion Cardioinfantil La Paz, La Paz, Bolivia; Department of Medicine, University of Colorado at Denver, Denver, Colorado USA; Bolivian Medical Centre of Surgery, Cochabamba, Bolivia

High altitude inhabitants with posttricuspidal shunts rarely develop severe pulmonary hypertension, and very late Eisenmenger Syndrome. The patients remain operable, and the pulmonary pressure remains reversible. We hypothesize thick pulmonary vessels are responsible for the stabilization of the vessel, which does not allow for the development of deformations, which are typical for the progressive disease of the vascular bed in pulmonary hypertension. Owing to a continuous vasoconstriction, the muscular media does not allow the high flow to the pulmonary vessels, which is typical for this condition. The aim of the clinical study is to assess if the patients with left to right shunts (ductus, VSD, ASD and AV channel) have a protective factor which impairs the development of pulmonary hypertension at early stages of the evolution of the disease at high altitude. Prospective, consecutive, case based a 1-year study with inclusion and exclusion criteria (VSD, PDA, or AV Channel patients older than 5 years with pulmonary hypertension and indication of surgical closure). All patients planned for (1) diagnostic catheter to assess operability and for invasive pulmonary pressure measures, (2), surgical correction of the CHD and lung biopsy, and (3) post-OP catheter for invasive pulmonary pressure measures. Four patients (Patient 1: 12-year-old boy with VSD; Patient 2: 28-year-old man with PDA; Patient 3: 11-year-old girl with VSD; and Patient 4: 10-year-old-boy with VSD) underwent cardiac catheterization with a hyperoxia test to assess operability. All four patients had pulmonary hypertension and the pulmonary pressures dropped with hyperoxia. Patients 1, 2 and 3 are already operated on and recovered well. Histological examination of the lung biopsies was suggestive of increased pulmonary artery medial thickness in all three cases but not more typical changes for advanced disease in the pulmonary vessels. Patient 4 is waiting for the operation. Patient 1 completed the three steps. The post-operative catheterization showed normal values for pressure and vascular resistance. High altitude exposure may be protective against severe irreversible congenital heart disease-associated pulmonary hypertension. The first study results are encouraging. We are looking forward to completing the series.

2.4: Long-term follow-up of closure of atrial septal defects in older children and adults with severe pulmonary arterial hypertension

Harikrishnan S, Sonney JP, Randeep S, Venkiteswaran S, Krishnamoorthy KM, Sivasankaran S, Titus T, and Jaganmohan T

Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, Kerala, India

The aim is to study the long-term outcome of older children and adults (\>5 years) with pulmonary arterial hypertension (PAH) who underwent surgical closure of atrial septal defects. Retrospective analysis of data of consecutive patients who had PAH and underwent ASD closure following an invasive hemodynamic study. The study included 38 patients (24 females). Mean age at the time of surgery was 24.8±11 years. Four (10%) had sinus venosus (SV) and 34 (90%) had ostium secundum (OS) defects. Preoperative (pre-op) PVR (pulmonary vascular resistance) or PVR Index\>4 wood units (WU) was the inclusion criteria. Left-to-right shunt ratio (QP/QS), systemic pressure (Ps in mmHg), pulmonary artery systolic pressure (Pp in mmHg), mean pulmonary artery pressure (PA mean), PVR and ration of PVR to systemic vascular resistance (Rp:Rs) were studied in all patients preoperatively. These parameters were reassessed after inhalation of 100% oxygen for 15 minutes in all patients. In the preoperative study, we saw a significant increase in QP/QS ratio (1.76±0.5 to 2.63±1.1), decrease in Pp (82±14.6 to 75.1±14.3) and PVR (8.9±2.8 to 5.23±1.7 WU) from the baseline after oxygen inhalation (P\<0.05). The mean follow-up was 12.4±6.3 years. Four patients were lost to follow-up. All the remaining 34 patients had clinical and echocardiographic follow-up, and were assessed for resolution of PAH, RV function and functional class. None of the patients had complete normalization of PA pressure on follow-up. Invasive hemodynamic study was done in 20 patients, at mean 6.2±3.8 years (6 months--12 years) following surgery. In these patients, there was a significant reduction in Pp (77.9±16.6 pre-surgery to 61.75±21.43 mmHg, post-surgery), Pp:Ps ratio (0.66±0.0.13 to 0.42±0.14) and PA mean (50.6±12.4 pre-surgery to 41±12 mmHg, post-surgery), but the reduction in PVR was not significant (8.59±2.80 to 7.03±3.80). Patients with basal PVR \>9 (N=14): five patients developed severe PAH on follow-up and four developed RV dysfunction and congestive heart failure (CHF). The pre-op response to O~2~ was not a significant predictor of outcome in this group. Patients with basal PVR \<9 (N=20): only one patient had worsening of PAH on follow-up. Majority of this group had regression of PAH to some extent, but most of them continued to have some degree of PAH on follow-up (RVSP 42±3.4 mmHg). Comparison of pre-op hemodynamic data between two groups (Group 1: patients with post-operative regression of PVR ≥20%, Group 2: post-operative regression of PVR\<20%) revealed a significant difference only in Qp:Qs following oxygen inhalation (P\<0.05). On multivariate analysis advanced age and basal PVR \>9 were significant predictors of non-regression of PAH and clinical worsening after ASD closure. ASD closure in patients with significant pulmonary arterial hypertension improved functional status, decreased PA systolic pressure and PA mean pressure but did not significantly alter the PVR. Complete resolution of PAH is uncommon on long-term follow-up. Patients with advanced age and preoperative PVR \>9 WU have significant risk of severe PAH, RV dysfunction and CHF on long-term follow-up.

2.5: Pulmonary hypertension in a tertiary health institution: A retrospective review of 24-months echocardiography registry

Sani MU, Mijinyawa MS, Ishaq NA, and Shehu MN

Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria

Pulmonary hypertension is a complex multidisciplinary disorder. It is a syndrome resulting from restricted flow to the pulmonary circulation leading to increased pulmonary vascular resistance and ultimately right heart failure. It is a devastating, progressive disease with increasingly debilitating symptoms and usually, shortened overall life expectancy. The epidemiology of PHT in sub-Saharan Africa has not yet been determined, but limited reports suggest that the incidence is higher than that reported from developing countries, owing to the pattern of diseases prevalent in the region. We set out to determine the primary cardiac diagnosis in patients with pulmonary hypertension found at echocardiography in Aminu Kano Teaching Hospital. Between September 2009 and August 2011 (a 24-month period), we retrospectively reviewed the primary cardiac diagnosis of all patients with pulmonary hypertension in our hospital. All the studies were trans-thoracic echocardiography done using ALOKA SSD-4000 machine. All measurements were done according to the recommendation of the American Society of Echocardiography (ASE). Continuous-wave Doppler was used to interrogate the valves when there was suspicion of any valvular lesion. Pulmonary artery systolic pressure (PASP) was estimated by measuring the Doppler systolic tricuspid regurgitant flow velocity and applying the Bernoulli equation and adding the right atrial pressure (RAP) which was assumed to be 10 mmHg. PHT was defined as mild if PASP was 35-45 mmHg, moderate if 46-60 mmHg and severe when PASP was \>65 mmHg. Information obtained from the records included age, gender, clinical diagnosis and echocardiogram findings. Data was analyzed using SPSS version 13.0 software. A total of 1411 echocardiographic examinations were done over the 24-month period. Of these, 256 (18.1%) had pulmonary hypertension, and they were analyzed. There were 117 males and 139 females, giving a male to female ratio of 1:1.2. The causes of pulmonary hypertension were hypertensive heart disease present in 80 patients (31.3 %), followed by cardiomyopathies (dilated and peripartum) seen in 57 patients (22.3%). Rheumatic heart disease and Corpulmonale were the causes in 46 (18.0 %) and 45 (17.5%) patients respectively. Other causes were ischemic heart disease in 10 (3.9%), idiopathic in 7 (2.7 %) and others in 11 (4.3 %). The others include three atrial septal defects and one case each of HIV infection, sickle cell disease, ventricular septal defect, Marfan\'s syndrome, thyroid heart disease, mitral valve prolapse, degenerative valve disease and hypertrophic cardiomyopathy. The most common cause of pulmonary hypertension from our echo registry is left heart disease, followed by lung disease i.e., corpulmonale (COPD and tuberculosis). HIV infection, schistosomiasis, chronic hepatitis B and C and Sickle Cell Disease are surprisingly rare causes, perhaps because of the nature of the study. There is need for a prospective registry to understand the epidemiology of this condition in Africa.

2.6: Overview of pulmonary hypertension registries and quality standards

Pittrow D

Institute of Clinical Pharmacology, Technical University of Dresden, Dresden, Germany

Registries are usually designed as multicenter cohorts of patients suffering from a specific disease, with long-term follow-up. As for other diseases, in pulmonary hypertension (PH) registries have become an important source of information as they provide data that cannot be captured in any other way (patient characteristics, practice patterns, outcomes and prognosis under everyday care conditions). Major currently active clinical PH registries include, but are not limited to, the REVEAL registry in the US, the CompERA-XL registry in several European countries, cohorts of the French National Registry, or the Spanish REHAB registry. These registries differ considerably in terms of scope, size, inclusion criteria, and length of follow-up. Thus, a global database has repeatedly been called for to unify such efforts. In contrast to clinical trials that usually follow the ICH-GCP guidelines that have been translated in national drug law legislation, for registries there are no generally accepted or mandatory quality standards. Depending on the groups who own or make use of the data, various guidance documents are being used, for example "Good Epidemiological Practice" (GEP), European Medicines Agency "European Network of Centres for Pharmaco-epidemiology and Pharmacovigilance (ENCePP) standards," Strengthening the Reporting of Observational Studies in Epidemiology" (STROBE), or "Cardiology Audit and Registration Data Standards" (CARDS) for registries conducted under the auspices of the European Society of Cardiology. Further, quality assurance elements of clinical trials are regularly applied, for example monitoring with source data verification. In pulmonary hypertension (PH) registries have become an important source of information as they provide data that cannot be captured in any other way (patient characteristics, practice patterns, outcomes and prognosis under everyday care conditions). Further standardization of key quality factors (completeness of data, extent of data validation, explicit definitions for variables etc.) would be helpful for PH registries, too.

2.7: Prognostic value of exercise cardiac index in idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension

Chaouat A

Service de Pneumologie, Hôpital de Brabois, CHU de Nancy, Nancy, France

In a study of incident cases of idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension (PAH) we studied the prognostic value of exercise cardiac index during right heart catheterization. Forty-three patients (22 women) with an age of 55 years (median) \[interquartile range (IQR): 46: 68\] were included. All patients had a right heart catheterization at rest and during an exercise of approximately 40% of the maximum workload. All patients were treated according to European guidelines and were followed up for from 6 to 144 months. At diagnosis, NYHA functional classes were I/II, III or IV in 7, 21 and 15 patients, respectively. Six-minutes walk test distance was 360 m. \[IQR 300: 430\]. Main pulmonary hemodynamic data at rest were mean pulmonary artery pressure of 50 mmHg \[IQR 43: 58\], cardiac index of 1.88 L/min/m^2^ \[1.59: 2.21\] and pulmonary vascular resistance of 1067 dyn.s.cm^-5^\[779: 1394\]. Patients with lower exercise cardiac index have a significantly higher NYHA functional class and lower 6-minutes walk distance. In a multiple stepwise regression analysis, only age and exercise cardiac index were predictor of the 6-minutes walk distance (r^2^=0.37, standard error of 95 m and P\<0.001) among all other clinical and pulmonary hemodynamic measurements performed at rest and exercise. Similarly, in multiple Cox survival analysis exercise cardiac index was the best predictor of death with a hazard ratio of 7.5 (95% confidence interval 2.3: 24.3, P=0.001). Exercise cardiac index is a better predictor of exercise capacity and survival compared with clinical and pulmonary hemodynamic data at rest in our cohort of patients with PAH.

2.8: Blockade of TGF-β prevents schistosomiasis-associated pulmonary hypertension

Graham B, Chabon J, and Tuder R

Program in Translational Lung Research, University of Colorado Denver, Denver, CO, USA

Schistosomiasis-associated pulmonary arterial hypertension (PAH) is one of the leading causes of PAH worldwide. We have previously found that TGF-β signaling is upregulated in human and experimental schistosomiasis-associated pulmonary hypertension (Sc-PH). TGF-β has been shown to be necessary for PH in monocrotaline and chronic hypoxia models of PH. We hypothesized blockade of TGF-β would prevent experimental Sc-PH. Wild-type mice (C57BL6/J background; 3-6 per group) were sensitized to *Schistosoma mansoni* eggs, and then intravenously challenged with 240 *S. mansoni* eggs/gram. A monoclonal pan-TGF-β neutralizing antibody, 1D11, or isotype IgG control, was administered every 3 days starting at the time of IV ova administration. 1D11 and IgG was also administered to uninfected mice in the same dosing schedule. One week after the IV ova administration, right ventricular catheterization was performed, followed by analysis of the lung tissue. Mice treated with IgG and infected with *S. mansoni* had an elevated right ventricular systolic pressure (RVSP) compared to uninfected IgG and 1D11 treated mice. However, mice treated with 1D11 and infected with *S. mansoni* did not have an elevated RVSP. Infected mice treated with 1D11 also had less pulmonary vascular remodeling than IgG-treated infected mice. 1D11 treatment had no effect on peri-egg granuloma volumes or the effectiveness of egg clearance. Inhibition of TGF-β may prevent Sc-PH without significantly compromising the host-immune response to the infection.

2.9: Platelet function and morphology in idiopathic pulmonary hypertension

Ramakrishnan S, Senguttuvan NB, Lakshmy R, Saxena R, Wadhwa S, Khunger JM, Bhargava B, Kothari SS, Saxena A, and Bahl VK

All India Institute of Medical Sciences, New Delhi, India

Pathogenesis of idiopathic pulmonary artery hypertension (IPAH) is not clear. Thrombosis and proliferation are the two important pathological features of IPAH. Theoretically, both these processes may be initiated by platelets. Clubbing and hypertrophic osteoarthropathy is currently explained by platelet-endothelium hypothesis. Escape of megathrombocytes from lung circulation due to any right-to-left shunt leads to platelet and endothelial activation in the nailbed that leads to clubbing. A similar barrage of activated platelets in the pulmonary circulation may lead to all the known pathological changes seen in IPAH. Nine consecutive patients of IPAH \[median age of 24 years (14-47 years)\] were included in the study. Nine patients with rheumatic heart disease with pulmonary hypertension and nine patients of RHD with PAH \[median age of 42 years (22-66 years)\] were recruited as controls. Patients of IPAH in NYHA Class IV status, decompensated heart failure, history of smoking, diabetes mellitus, coronary artery disease, associated hematological disorder, hepatic or renal dysfunction, and patients who were taking NSAIDs or aspirin in the last 1 week, were excluded from the study. All patients underwent cardiac catheterization. Blood samples were taken from superior vena cava, pulmonary artery, left ventricle and femoral artery. Collagen and Adenosine-di-phosphate were utilized for the assessment of platelet reactivity. Samples of blood from the different sites in each patient were utilized for the analysis of platelet morphology under electron microscopy. The morphology of visualized platelets was utilized for the purpose of classifying them into active, partially active and inactive. The pulmonary artery pressures, right ventricular systolic pressure and pulmonary vascular resistance were significantly higher in IPAH group, while the pulmonary capillary wedge pressure was higher in the control group. There was no difference in the proportion of active platelets between IPAH group and the control group at various sites. In the IPAH group, the number of active platelets was significantly higher in pulmonary artery as compared to that of femoral artery (P=0.01). In contrast, there was no difference in the number of active platelets between various sites in patients with RHD with PAH. Platelet reactivity at the various sites did not differ significantly between IPAH and RHD with PAH groups. There was no significant difference in platelet reactivity measured biochemically by collagen and ADP between pulmonary artery and the rest of the sites. We found an increased existence of active platelets in pulmonary circulation as compared to systemic circulation by electron microscopy in IPAH patients. We found no difference in the level of platelet reactivity between pulmonary and systemic circulation biochemically. Patients with IPAH did not show significantly high platelet reactivity as compared to the patients with RHD with moderate to severe PAH.

2.10: Prevalence of pulmonary hypertension among 6270 asymptomatic school children in India: The Rheumatic Heart Echo Utilization and Monitoring Actuarial Trends in Indian Children Study

Saxena A, Ramakrishnan S, Roy A, Seth S, Krishnan A, Misra P, Kalaivani M, Bhargava B, Flather M, and Poole-Wilson P

All India Institute of Medical Sciences, New Delhi, India; Royal Brompton Hospital and Imperial College, London, UK

The prevalence of pulmonary artery hypertension (PAH) among school children in India is not known. Conventionally, auscultation has been used for community screening for heart disease, but echocardiography with Doppler may be more sensitive and specific. Hence, in the Rheumatic Heart Echo Utilization and Monitoring Actuarial Trends in Indian Children study designed to identify echocardiographic prevalence of rheumatic heart disease, we estimated the prevalence of PAH. We carried out a cross-sectional survey to diagnose heart defects in asymptomatic school children aged 5-15 years, living in rural areas, using portable echocardiography. The demographic data were collected. After history and physical examination, echo-Doppler was performed, using a bedside portable echocardiography machine. A total of 6,270 asymptomatic children were screened and 52% were male. The mean age was 10.79±2.63 years. Echo-Doppler diagnosed pulmonary hypertension in four cases, giving a prevalence of 0.6/1000 school children (90% CI -- 0.1 -- 1.1/1000 children). The cardiac lesions associated with PAH identified by echo-Doppler included: rheumatic heart disease (two patients), Eisenmenger syndrome (one patient), and one patient of atrial septal defect with mitral regurgitation and PAH. The prevalence of PAH among children in India is higher than reported from the developed world. The common causes of pulmonary hypertension in children are rheumatic heart disease and un-operated congenital heart disease in developing nations.

2.11: A review of catheterization data for determining operability in congenital heart disease with severe pulmonary hypertension

Juneja R, Ramakrishnan S, Anju, Gupta S, Kothari SS, and Saxena A

All India Institute of Medical Sciences, New Delhi, India

Pulmonary artery hypertension (PAH) complicates the clinical course and outcome of many patients with congenital heart disease (CHD) and is an important determinant of morbidity and mortality in these patients. Surgical correction at the correct time is the only method known to prevent these complications. There are several limitations in the present way of determining operability. We started prospectively collecting data of all patients getting catheterized with a diagnosis of left-to-right shunts with severe PAH. Patients were divided into three categories based on the final recommendation of the cardiologist/cardiac surgeon. Group I: likely operable; Group II: definitely inoperable (Eisenmenger); and Group III: borderline operability. Of the 100 patients included (mean age 8.5 years) the majority had ventricular septal defect (67%). Forty-six patients were considered operable (Group 1), 17 patients were considered inoperable, and 27 patients were classified as borderline operability. PAH secondary to left-to-right shunts remains a major problem in our country. Basal PVRI, pulmonary blood flow and Qp/Qs ratio, and post-oxygen fall in pulmonary diastolic pressure and PVRI help in the determination of operability.

2.12 Predictors of adverse clinical outcome in Eisenmenger syndrome

Ramakrishnan S, Kukreti BB, Juneja R, Bhargava B, Kothari SS, Saxena A, and Bahl VK

All India Institute of Medical Sciences, New Delhi, India

Clinical course and predictors of adverse events in Eisenmenger syndrome are not well characterized. In this interim analysis, we present the data of 50 patients of Eisenmenger syndrome followed up for a mean duration of 18.2 months (range 2-84 months). Routine clinical examination and 6-minute walk test were done at enrolment and follow-up visits. Fifty patients of Eisenmenger syndrome of mean age 24 10 years were followed up for mean duration of 18 months (range 2-84 months). Mean 6-minute walk distance was 475.23±101.4 meters at enrolment and 486.2 115.5 meters at follow-up. Adverse events (worsening heart failure and death) were seen in seven patients. Adverse events were significantly correlated with follow-up 6-minute walk distance 509±90 versus 348 161 meters (P=0.011) and post 6-minute walk heart rate. Worsening of 6-minute walk distance is a useful and powerful predictor of clinical worsening in Eisenmenger syndrome patients.

2.13: Nocturnal hypoxemia in patients with Eisenmenger syndrome

Ramakrishnan S, Juneja R, Sharma AK, Bardolei N, Shukla G, Guleria R, Bhatia M, Kalaivani M, Kothari SS, Saxena A, and Bahl VK

All India Institute of Medical Sciences, New Delhi, India

Significant nocturnal hypoxemia occurs in patients with obstructive pulmonary disease and primary pulmonary hypertension. Nocturnal hypoxemia may also be important in patients of Eisenmenger syndrome (ES), but has not been assessed so far. The objective of the study was to find the prevalence of sleep-related disturbances in patients with ES. The study included 25 patients with ES (mean age 25.2±9.6 years, 18 male) and 12 patients with cyanotic congenital heart disease (CCHD) with pulmonary stenosis physiology (mean age 20.5±8.5 years, eight male) as controls. All the patients underwent an overnight comprehensive polysomnogram study. An oxygen drop is defined as any fall in SpO~2~ greater than 5% lasting for at least 9 seconds. Oxygen desaturation index (ODI) is the number of oxygen desaturations per hour. The patients and controls had significant nocturnal hypoxemia in the absence of apnea and hypopnea. The mean ODI in ES group was 9.0±6.2 and in CCHD with pulmonary stenosis group was 8.0±5.9 (P=0.63). The apnea hypopnea index (AHI) was 3.37±5.0 in the ES group and was 2.1±3.6 in CCHD with pulmonary stenosis group. Patients with ODI\>10 had significantly higher hemoglobin (17.2±1.3% versus 14.4±1.5%, P\<0.001) than those with ODI\<10. Eisenmenger syndrome patients have significant nocturnal hypoxemia unrelated to hypopnea and apnea. Nocturnal desaturation occurred more frequently in patients with greater hemoglobin values. These findings may have important therapeutic implications.

2.14: Pulmonary hypertension at moderate altitude in children: Importance of the hyperreactivity of pulmonary vascular tree

Díaz GF

National University, Bogota, Colombia

The hypobaric hypoxia gives special characteristics to pulmonary hypertension (PH) at altitude related to biopathogenesis, epidemiology, diagnostic approach and treatment. One aspect related to the biopathogenesis is the hyperreactivity, a characteristic that must be studied with precision in the patients at altitude, having in mind its importance related to prognosis and treatment. Due to the importance of the hypobaric hypoxia and the hyperreactivity of pulmonary vascular tree at altitude, we decided to study the effect of the prolonged hyperoxic test (oxygen with FiO~2~ \>80% for more than 1 hr.) in children living in Bogota, Colombia at 2.640 meters above sea level (moderate altitude). Children with severe pulmonary hypertension diagnosed with echocardiogram confirmed by catheterism were exposed to oxygen (FiO~2~ \>80%) for more than 1 hour (1-24 hrs.) after a basal echocardiogram without oxygen. We measured the pulmonary pressure using the Bernoulli equation after getting an excellent tricuspid regurgitation curve. Of the 15 patients, 13 had idiopathic pulmonary hypertension and 2 had PH and VSD: 1 too small muscular VSD and 1 large VSD. All patients were with oxygen and in functional Class III or IV and 1 was in very critical situation. The median of the pick systolic pulmonary pressure (PSPP) before the proof was 92 mmHg (81-161) and the median of the PSPP after the proof was 61 mmHg. One patient did not respond to the proof and died 4 months later. Eight patients went to live at low altitude, are alive and asymptomatic with a follow-up between 6 months and 28 years (median: 8.2 years) with PSPP between 44 and 56 mmHg. The more critical patient with initial PSPP of 153 mmHg is asymptomatic with a follow-up of 10 years and PSPP of 46 mmHg. The patient with large VSD was rejected for surgery; however, after the positive extended hyperoxic test, the patient went to live at low altitude with sildenafil and 6 months later was re-catheterized. We found that the pulmonary resistances were at their lowest, the VSD was closed by surgery and at this moment the patient is asymptomatic with a follow-up of 6 years. One patient with very positive extended hyperoxic proof could not afford to live at low altitude for socioeconomic problems and died 6 months later. The other five patients could not live at low altitude due to a number of factors. Of them, four continue with severe PH and whilst the fifth patient experienced a rise in the pulmonary pressure and is in a critical clinical situation. The hyper-reactivity of the pulmonary vascular tree is an important characteristic of PH at altitude. As the hypobaric hypoxia is important in the biopathogenesis of PH at altitude, the oxygen is an effective vasodilator of the pulmonary vascular tree. We found that the prolonged hyperoxic test is an important tool to evaluate the hyper-reactivity of the pulmonary vascular tree at altitude. The patients with hyper-reactivity of the pulmonary vascular tree at altitude must live at low altitude to increase their chances of survival.

2.15: Novel roles of radiation protective compound amifostine in attenuation of acute lung injury

Birukov KG, Fu P, Sarich N, and Birukova AA

Department of Medicine, University of Chicago, Chicago, IL, USA

Acute lung injury (ALI) and adult respiratory distress syndrome (ARDS) remain serious life-threatening conditions with 30% morality and limited therapeutic treatment opportunities. Acute inflammation and vascular leak are cardinal features of ALI/ARDS. Nonspecific tissue inflammation and injury in response to infectious and noninfectious insults (i.e., high tidal volume mechanical ventilation (HTV)) lead to oxidative stress, which further exacerbates tissue injury and inflammatory processes in the lung. Despite an encouraging outcome of antioxidant therapy in animal models of acute lung injury, effective antioxidant agents for clinical application remain to be developed. Amifostine is an FDA-approved radiation protection agent with antioxidant and DNA-protective properties used to prevent surrounding tissue damage during radiation therapy. Amifostine mitigating effects have been also tested in the models of toxic tissue injury. This study tested two hypotheses: (a) concurrent treatment with amifostine may reduce lung endothelial barrier dysfunction and lung inflammation caused by Gram-negative bacteria wall-lipopolysaccharide (LPS) by direct mitigation of LPS-induced oxidative stress; and (b) preconditioning with very low doses of amifostine may be protective against ventilator induced lung injury due to induction of endogenous antioxidant defense mechanisms. Concurrent treatment with amifostine abrogated LPS-induced ROS production leading to inhibition of LPS-induced endothelial permeability and redox-sensitive signaling cascades: p38 and Erk-1,2 mitogen-activated protein (MAP) kinases and the nuclear factor-kappaB (NFkB) pathway. In vivo, concurrent amifostine administration inhibited LPS-induced tissue oxidative stress and reduced vascular leak and neutrophil recruitment to the lungs. In turn, 3-day preconditioning with low doses of amifostine prior to HTV attenuated HTV-induced protein and cell accumulation in the alveolar space judged by BALF analysis, decreased Evans Blue dye extravasation into the lung parenchyma, decreased biochemical parameters of HTV-induced tissue oxidative stress, and inhibited HTV-induced activation of redox-sensitive stress kinases and NF-κB inflammatory cascade. These protective effects of amifostine were associated with increased superoxide dismutase 2 (SOD2) expression and increased SOD and catalase enzymatic activities in the animal and endothelial cell culture models of VILI. These results suggest that, besides direct antioxidant effects, amifostine preconditioning activates lung tissue antioxidant cell defense mechanisms and may be a promising strategy for alleviation of VILI in critically ill patients with sepsis subjected to extended mechanical ventilation.

2.16: Atrial natriuretic peptide improves

Staphylococcus aureus

-induced lung inflammation and vascular barrier function

Birukova AA, Xing J, and Moldobaeva N

Department of Medicine, University of Chicago, Chicago, IL, USA

Lung inflammation and alterations in endothelial cell (EC) permeability are key events to development of acute lung injury (ALI). This study investigated effects of atrial natriuretic peptide (ANP) on pulmonary endothelial barrier dysfunction caused by components of Gram-positive bacterial cell wall, *Staphylococcus aureus*-derived peptidoglycan (PepG) and lipoteichoic acid (LTA). C57BL/6J wild type or ANP knockout mice (Nppa-/-) were treated with a combination of LTA and PepG (i/t, 2.5 mg/kg each) with or without ANP (i/v, 2 μg/kg). In human pulmonary endothelial cell culture barrier properties were assessed by morphological analysis, measurements of transendothelial electrical resistance, and phosphorylation profile of signaling proteins. Heat inactivated *S. aureus* bacterial particles, LTA and PepG increased pulmonary EC permeability, which was associated with activation of Rho, MAP kinase, and NFκB signaling, which was further promoted by combined LTA and PepG treatment. Disruptive effects of LTA and PepG were abolished by ANP pretreatment. In vivo, accumulation of protein and cell elements in the bronchoalveolar lavage fluid, tissue neutrophil infiltration, and increased Evans blue extravasation reflecting lung vascular leak caused by intratracheal LTA and PepG instillation were significantly attenuated by intravenous injection of ANP. BAL markers of LTA/PepG-induced lung dysfunction were further augmented in ANP^-/-^ mice. These results strongly suggest a protective role of ANP in the in vitro and in vivo models of acute lung injury associated with Gram-positive infection. Thus, ANP may have important implications in therapeutic strategies aimed at the treatment of sepsis and ALI-induced Gram-positive bacterial pathogens.

2.17: Oxygen sensing pathway: Revealing and documenting human adaptations at high altitude

Mishra A, Thinlas T, Mohammad G, and Pasha Q

Institute of Genomics and Integrative Biology, Delhi, Department of Biotechnology, University of Pune, Pune, and Department of Medicine, SNM Hospital, Leh, Ladakh, India

The residents of Great Himalayas have evidence of positive selection on genetically based trait variation counteracting the effect of environmentally induced changes. These residents have many visible adaptive changes like higher resting ventilation, low hemoglobin concentration, thin-walled pulmonary vasculature, higher exhaled nitric oxide and blunted hypoxic vasoconstriction response that helped them live reproducibly and successfully for thousands of years. The genes of oxygen sensing pathway have emerged the most favorite candidates for genetic adaptation at HA. For example, the two main components *Endothelial PAS domain-containing protein 1 (EPAS1)* and HIF-1 Prolyl hydroxylase 2 (*EGLN1*) of HIF-signaling pathway have shown the evidence of positive selection in recent genome-wide association studies (GWAS). The selected regions of both the genes by exhibiting an association with low Hb concentration indicate their strong functional and regulatory role in maintenance of adaptive homeostasis at HA. The case-control design conducted by us enumerated the selection of *EGLN1* with T allele of rs480902 and C allele of rs479200 in HA population (P=4.01E-07). Conversely, the T allele of rs479200 that corresponded to higher expression of *EGLN1* was overrepresented in HAPE (P\<0.05) when compared with healthy sojourners at the same environment. In addition to *EPAS1* and *EGLN1*, other two candidates of this pathway, namely *endothelial nitric oxide synthase (NOS3)* and *endothelin-1 (ET-1)*, also deserve description. The 298Glu allele of 298Glu/Asp polymorphism and 4b allele of 4b/4a (27 base pair variable number tandem repeat) of *NOS3*; longer-repeats of (CT)n--(CA)n repeat and G allele of 2288G/T polymorphism of *ET-1* were overrepresented in the natives (P≤0.05) whereas 298 Asp allele of 298Glu/Asp and 4a allele of 4b/4a of *NOS3*; shorter-repeats of (CT)n--(CA)n repeat and T allele of 2288G/T of *ET-1* were found to be associated with HAPE (P≤0.05). Surprisingly, however, GWAS has not shown selection of these two or several other markers as adaptation and mal-adaptation is multigenic trait. The evidence of just one or few signals out of millions of SNP in GWAS definitely suggests of improvement in statistical and computational software currently in use so that complete information can be captured from such an expensive, extensive and exhaustive study. Nevertheless, these studies have clearly documented the evolutionary selection of genetic variants specific to high-altitude Tibetans which have helped them achieve oxygen saturation and hematological profile similar to normoxic condition.

2.18: Vasoactive mediators and ROS interactions under hypobaric hypoxia

Ali Z, Mishra A, Mohammad G, and Pasha Q

Institute of Genomics and Integrative Biology, Delhi, Department of Biotechnology, University of Pune, Pune, and Department of Medicine, SNM Hospital, Leh, Ladakh, India

The hypobaric hypoxic environment, UV radiation and cold temperature at high-altitude induces many changes like hypoxic pulmonary vasoconstriction response, blunted hyperventillatory response, increased hemoglobin concentration and sympathetic nervous response. This extreme environment is also responsible for the increased production of reactive oxygen species (ROS) and alleviated antioxidant capacity of body. Thus, hypoxia-mediated oxidative stress is central to the development of HA related disorders in both sojourners and permanent residents of HA. ROS is responsible for impairment of redox homeostasis, damage to lipids, proteins, DNA and different organs, and is also a modulator of SMC proliferation, vascular remodeling and dysfunction. It has proliferative roles and act as a secondary messenger in receptor-mediated signaling pathways mediated by potent vasoconstrictors like endothelin-1 (ET1) and 8-iso-prostaglandin F2α (8-iso-PGF2α) at HA. ET-1, a 21-amino acid polypeptide produced by vascular endothelial cells has mitogenic effect on SMCs whereas 8-iso-PGF2α, produced by the random oxidation of tissue phospholipids by oxygen radicals, is a potent vasoconstrictor. Therefore, both have vasoconstrictory role in the vasculature. ROS decrease the NO mediated vasodilatory action by combining with NO to generate peroxynitrite, a highly reactive nitrogen species (RNS) that further oxidizes low density lipoprotein (LDL) and supplements peroxidative stress at HA. The differential level of NO, ET-1, 8-iso-PGF2α and partial pressure of oxygen (SaO~2~) in HA natives compared to healthy sojourners at the same altitude depicts the physiological hypoxia in them (P≤0.01). The inverse correlation of ET-1 and 8-iso-PGF2a with SaO~2~ suggests the reduced bioavailability of O~2,~ as the consequence of oxidative overload in HA natives (P≤0.05). Similarly, the positive interaction of NO levels with SaO~2~ is suggestive of this molecule trying to maintain stability (P≤0.05); in addition, involvement of some assorted mechanisms in mediating protective response against oxidative damage is not ruled out. Therefore, the higher level of vasoconstrictors and ROS in HA natives advocate that this population of HA living for thousands of years is continually under stress. The exploration of intricate mechanism behind the interaction of these vasoactive mediators and ROS will not only help in alleviating the physiological stress at HA but will also be relevant in numerous other cardiovascular and respiratory disorders sharing similar pathophysiological features.

2.19: Interkinase communiqué: The P Code

Pandey P, Mohammad G, and Pasha Q

Institute of Genomics and Integrative Biology, Delhi, Department of Biotechnology, University of Pune, Pune, Department of Medicine, SNM Hospital, Leh, Ladakh, India

Kinases, a set of mechanistically and evolutionarily distinct enzymes, involved in the transfer of high-energy phosphate moieties, have become an important target in the discovery of newer drugs. Numerous cellular processes like cell signaling, cell division and growth, development, differentiation, and cell death are orchestrated by interaction between a series of spatially distributed kinases. Although phosphorylation surges govern these interactions in cellular metabolome, the essential regulatory details of these signal conducing moieties remain inexplicable till date. This cascade under stable homeostatic conditions is tightly regulated but under strenuous settings such as oxidative stress it becomes unregulated culminating in the disruption of the intracellular signaling networks. Oxidative stress at high altitude leads to altered kinase functioning as is evident in pulmonary vasculature leading to pulmonary hypertension-a hallmark of high altitude-related disorders. Tyrosine kinases remain the class of kinases most investigated, closely followed by serine and threonine kinases as targets for therapeutic intervention. Eukaryotic kinases have a conserved reaction mechanism of catalysis which enables them to be drugged by several small molecular weight inhibitors. Studies in pulmonary hypertensive mice models have provided a breakthrough; i.e., inhibition of Rho kinase with its specific inhibitor fasudil has depicted significant alleviating results. However there also exist interindividual differences toward therapies; hence an approach is needed that can explain about the hyper- and hypo-responsiveness among the individuals. In view of this, several candidate kinases majorly implicated in pulmonary hypertension have been picked up by us for analysis in a case-control design. To start with, 10 polymorphisms of Rho kinase have been studied; 6 out of 10 have given significant results (P\<0.05). A number of circulatory markers involved in the candidate kinase pathway have also been measured and correlated with different clinical characteristics with significant correlations (P\<0.05). Activity measurement of selected kinases is in progress. Studies have provided a lead in better understanding the kinases but the interaction between these diverse ranges of phosphorylating or P-moieties remains to be elucidated.

2.20: Causes of pulmonary arterial hypertension in the pediatric population in a tertiary care center in Saudi Arabia

Banjar H

Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia

Pulmonary arterial hypertension (PAH) has been frequently described in the pediatric population. Approximately 40% of cases of pulmonary arterial hypertension are idiopathic, and 6% are heritable in nature, with the remaining mainly associated with congenital heart disease and few associated with connective tissue diseases, human immunodeficiency virus (HIV), or portal hypertension. Mortality associated with pulmonary arterial hypertension is extremely elevated. Once diagnosis has been confirmed, mean survival among adults is 2.8 years and less than 1 year among children. My objective was to identify the different causes and outcomes of PAH and treatment modalities in referred cases to the pediatric pulmonary clinic in a tertiary care center in Saudi Arabia. Retrospective chart review of all referred patients to pulmonary clinic with documented PAH based on cardiac catheterization and or Echocardiogram during a 1-year period (March 2009-February 2010). A total of 114 patients with confirmed PAH. Mean age at diagnosis 3.1 up to 3.8 years. Of these patients, 55 (48%) were males and 59 (52%) were females. The most common cause of pulmonary arterial hypertension was found to be congenital heart disease (CHD): CHD was diagnosed in 100 patients (87.7%). The most common congenital heart diseases that caused pulmonary hypertension were: atrial septal defect (ASD) in 76 patients (67%); ventricular septal defect (VSD) in 63 patients (55%); common atrio ventricular canal (Common A-V Canal) in 39 patients (34%); patent ductus arteriosus (PDA) in 16 patients (14%); tetralogy of Fallot (TOF) in 11 patients (10%); and total anomalous pulmonary venous return (TAPVR) in 2 patients (1.7%). Other causes of pulmonary arterial hypertension were congenital anomalies in 100 (87.7%), and Down syndrome in 44 (38.5%); and 39 of 44 patients (88%) with Down syndrome had congenital heart disease. Other congenital anomalies were CHARGE association, and skeletal dysplasia, and 32 patients had an unknown syndrome. Eleven patients (10%) had congenital lung anomalies as diaphragmatic hernia in association with lung hypoplasia, and congenital lobar emphysema; 11 patients (10%) had chronic lung disease (CLD); 2 patients were living in high altitude; 2 patients had obesity; 2 patients had Alagile syndrome; and 2 patients had idiopathic PAH. Obstructive sleep apnea (OSA) was detected in 31 patients (27%), asthma in 33 (30%), and recurrent chest infection in 41 (36%). Thirty-two patients (28%) required O~2~, and 36 (32%) were found to have gastroesophageal reflux (GER). Factors that related to the development of PAH at presentation were found to be: Common A-V Canal P-value =0.3205; and OSA P-value=0.0266, with a female sex P-value=0.05. Sixty of 114 patients (53%) were started on vasodilators. Sildenafil (Revatio) was the most common drug used in 35 patients (30%) alone or in combination with Bosentan (Tracleer) or inhaled Ventavis (Iloprost). Bosentan alone or in combination was used in 21 patients (18%) and inhaled Ventavis alone or in combination in 8 patients (4%). At follow-up, 75 patients (66%) continued to have PAH. The factors that contributed to persistence of PAH at follow-up included the presence CHD P-value=0.05, unclosed ASD P-value=0.03. Pulmonary hypertension is a common disease and should be diagnosed and treated early before it becomes irreversible and resistant to vasodilators. Early closure of ASD and CHD defect repair improves PAH.

2.21: Involvement of immune/inflammatory cells to pathology of idiopathic pulmonary arterial hypertension

Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Ghofrani HA, Weissmann N, Fink L, Klepetko W, Voswinckel R, Banat GA, Seeger W, Grimminger F, and Schermuly RT

Departments of Lung Development and Remodelling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany; Departments of Internal Medicine and Pathology, University of Giessen Lung Center, Giessen, Germany; and Departments of Thoracic Surgery, University Hospital Vienna, Vienna, Austria

Pulmonary arterial hypertension (PAH) is a devastating disease characterized by abnormal increased vasoconstriction and vascular remodeling. Recent studies have revealed that both immune and inflammation responses play a crucial role in pathogenesis of idiopathic PAH (IPAH). In the present study, we systematically evaluated the distribution and the numbers of immune/inflammatory cells in different categories of pulmonary arteries (20-50 μm, 51-150 μm and \>150 μm) from explanted lungs of IPAH patients (versus donors) by using immunohistochemical and morphometric techniques. Quantification of the immune/inflammatory cells showed a significant increase of macrophage (CD68+), mast cell (toluidine blue +), dendritic cell (CD209+), T-cell (CD3+) and cytotoxic T-cell (CD8+) count in IPAH lungs as compared to controls. Moreover, there was a significant accumulation/infiltration of these cells in smaller (20-50 μm) and medium (51-150 μm) size pulmonary arteries. Analysis of T-regulatory (Treg) cells (FoxP3-positive) showed a significant decrease in the lungs; furthermore, an absence or low number of Treg cells was observed in remodeled pulmonary vasculature of IPAH patients. Our findings show alterations in immune/inflammatory cell infiltrations in pulmonary vascular lesions of IPAH patients. Thus, targeting immune/inflammatory cells may be a novel approach to treat IPAH and can be used to monitor the disease process.

2.22: Nonresponse to acute pulmonary vasodilator challenge in idiopathic pulmonary arterial hypertension is associated with nonrecruitment of pulmonary functional capillary endothelial surface area

Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Sotiropoulou Ch, Armaganidis A, and Catravas JD

Jewish General Hospital, McGill University, Montreal, Quebec, Canada; Attikon Hospital, University of Athens Medical School, Haïdari Athens, Greece; Medical College of Georgia, Augusta, GA, USA

Acute pulmonary vasodilator challenge is used in patients with idiopathic pulmonary arterial hypertension (IPAH) as a method of predicting responsiveness to high-dose calcium channel blockers. Based on current criteria, most patients are characterized as nonresponders (i.e., they fail to lower their mean pulmonary arterial pressure by at least 10 mmHg to less than 40 mmHg, under unchanged or higher cardiac output (CO). Many nonresponders depict CO increases resulting in a decreased calculated pulmonary vascular resistance (PVR). It is not known if an acute vasodilator challenge is able to recruit underperfused or nonperfused pulmonary microvessels, and whether the increased blood flow seen in nonresponders represents recruitment of microvasculature. It is also unclear how the change in PVR relates to recruitment. Eleven patients with IPAH underwent cardiac catheterization as part of their diagnostic workup. Standard hemodynamic variables were measured before and after an acute vasodilator challenge with intravenous epoprostenol. All subjects were characterized as nonresponders. Applying indicator-dilution type techniques twice, prior to the challenge and at peak epoprostenol dose, we measured first pass transpulmonary percent metabolism (%M) and hydrolysis (v) of the synthetic and highly specific substrate 3H-benzoyl-Phe-Ala-Pro (BPAP) by the pulmonary capillary endothelium-bound angiotensin converting ectoenzyme (ACE), under first-order reaction conditions. We also measured functional capillary surface area (FCSA), previously termed A~max~/K~m~, normalized to body surface area (BSA). Data are given as mean±SD. With vasodilator challenge, mPAP did not change significantly (62±13 mmHg pre versus 60±12 post). CO increased (3.26±1.50 L/min pre versus 4.32±1.88 post, P\<0.001). PVR decreased from 18.8±10.5 Wood units pre to 13.1±5.3 post (P=0.04). BPAP % metabolism was reduced from 64.1±13.4% pre, to 55.4±14.2% post (P\<0.001), and BPAP hydrolysis (v) decreased from 1.10±0.43 pre to 0.87±0.41 post (P\<0.001). However, FCSA/BSA did not change significantly (1201±555 mL/min/m^2^ versus 1246±555). There was a negative linear relationship between percent change in FCSA/BSA and absolute or percent change in PVR (r=-0.754, P\<0.01 and r=-0.597, P=0.052, respectively). The acute vasodilator challenge in our IPAH cohort of non-responders failed to recruit FCSA, despite the observed increase in pulmonary blood flow and the drop in calculated PVR. This is likely because the degree of upstream structural arteriolar remodeling in these patients was advanced. The absence of FCSA changes along with the observed fall in %M and v post acute challenge suggest that the higher pulmonary blood flow passes the lung via already perfused microvessels with a quicker transit time (i.e., enzyme-substrate reaction time) and probably causes some vessel distension, resulting in lower substrate utilization. This study provides a mechanistic explanation for the poor vasodilator response in these patients, despite a fall in calculated PVR.

2.23: Utility of the brain natriuretic peptide as a marker in the diagnosis of patients with persistent pulmonary hypertension of the newborn

Díaz G, Ruiz AI, Acherman R, Montealegre A, Ome L

and Marquez A

Universidad Nacional de Colombia, Instituto Materno Infantil, Bogotá, Colombia; Children΄s Heart Center Las Vegas, Nevada; University of Nevada Las Vegas, NV, USA

The brain natriuretic peptide (BNP) is a hormone secreted in excess by the ventricles in situations of pressure or volume overloud. Our objective was to analyze the utility of BNP as a marker of persistent pulmonary hypertension of the newborn (PPHN). We studied 52 neonates with PPHN diagnosed by clinical findings and echocardiogram. The diagnostic criteria were a pulmonary systolic pressure over 80% of the systemic pressure measured simultaneously, with clinical findings of pulmonary hypertension. Patients with hypotension or congenital heart disease excepting ductus arteriosus were excluded. Nine control neonates were included for comparison. A blood sample for BNP was taken after the echocardiogram. The sample was collected in tubes with EDTA and centrifuged. BNP was determined by immunoradiometric assay using the Triage Meter Plus device (Biosite). The laboratory technician was masked about the clinical situation and the results of the echocardiograms. The statistic analysis was made with the STATA 8.0 software using descriptive statistics, Shapiro-Wilk test for normality, and Kruskal Wallis test for comparison. All patients were treated with Sildenafil 2 mg/kg/day. The median of the pretreatment pulmonary systolic pressure (PSP) was 56 mmHg (percentile 25: 52.5 mmHg; percentile 75: 62.5 mmHg; range: 48-91 mmHg). The median of the post-treatment PSP was 25 mmHg (percentile 25: 24 mmHg; percentile 75: 33 mmHg; range: 16-60 mmHg) p: 0.0000 pre versus post-treatment. The median of the basal BNP was 408 pg/ml; (percentile 25: 139 mmHg; percentile 75: 3670 pg/ml; range 5-5501). The median of the BNP post-treatment was 72 pg/ml; (percentile 25: 10.65 pg/ml; percentile 75: 277 pg/ml; range 5-2240). P: 0.012 pre versus post-treatment. In the control group the median of BNP was\<5 pg/mL. BNP is a good marker in the diagnosis and follow-up of patients with persistent pulmonary hypertension of the newborn.

2.24: Sildenafil plasma concentrations in two HIV patients with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitors

Chinello P, Cicalini S, Pichini S, Pacifici R, Tempestilli M, and Petrosillo N

Second Infectious Diseases Unit and Clinical Biochemistry and Pharmacology Laboratory, "L. Spallanzani" National Institute for Infectious Diseases, Rome, Italy; Department of Therapeutic Research and Medicines Evaluation, Drug Abuse and Doping Unit, Instituto Superiore di Sanità, Rome, Italy

Sildenafil is increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions between sildenafil and protease inhibitors (PI); in particular, ritonavir has been shown to increase sildenafil AUC and C~max~ by several fold. Data on the pharmacokinetic of sildenafil in HIV-PAH patients treated with antiretroviral therapy (ART) including ritonavir are scant. The aim of our study was to determine the plasma levels of sildenafil and PI in two HIV patients with PAH treated with ART including ritonavir-boosted PI. Plasma concentrations of sildenafil and N-desmethylsildenafil were evaluated before the intake of the 20 mg sildenafil dose (T~0~) and 2 h thereafter (T~2h~), twice in the same day. Heparinized venous blood samples were collected in 7.5-mL tubes and were stored after centrifugation at -80°C until analysis. Sildenafil and desmethylsildenafil were measured in plasma by a liquid chromatography tandem mass spectrometry published methodology, in-house revalidated for the inclusion of N-desmethylsildenafil. Plasma concentrations of lopinavir, amprenavir, and ritonavir were assessed before the intake of the daily PI dose (T~0~) and 1, 2, 4, and 6 hours thereafter (T~1h~, T~2h~, T~4h~, and T~6h~). PI concentrations were measured in plasma by a validated high-performance liquid chromatography method. Two hours after the morning assumption of sildenafil, Patient 1 had a sildenafil C~max~ of 655.2 ng/mL, and Patient 2 had a sildenafil C~max~ of 515.4 ng/mL. For Patient 1, the C~through~ of ritonavir and lopinavir were \<39 ng/mL and \<117.2 ng/mL, respectively; the C~max~ of ritonavir and lopinavir were 184 ng/mL and 6800 ng/mL, respectively. For Patient 2 the C~through~ of ritonavir and amprenavir were \<39 ng/mL and 2007 ng/mL, respectively; the C~max~ of ritonavir and amprenavir were 147 ng/mL and 3770 ng/mL, respectively. According to the European Medicines Agency review of Revatio, a sildenafil plasma concentration between 10 and 100 ng/mL is associated with a significant effect on pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR); maximal reductions in PAP and PVR are obtained at plasma concentrations in the range of 100 ng/mL. Both of our patients experienced C~max~ above 500 ng/mL; however, they did not report any adverse reactions to sildenafil, such as headache, flushing, dyspepsia or priapism; there was no significant influence on systemic blood pressure, which was measured regularly during the investigations. After a 1-year follow-up, the patients are in satisfying general conditions, without significant sildenafil-related adverse events. In conclusion, in our patients the coadministration of sildenafil and ritonavir-boosted PI resulted in an increase of sildenafil plasma concentration above the therapeutic range; however, this increase did not cause significant adverse events in the follow-up period. Therapeutic drug monitoring of sildenafil should be taken in consideration during therapy in order to avoid over-dosage in patients concomitantly treated with ritonavir-boosted PI.

2.25: Estimation of pulmonary artery pressure in patients with sickle cell anemia in Ibadan, Nigeria: An echocardiographic study

Enakpene EO, Adebiyi A, Ogah OS, Olaniyi JA, Aje A, Adebayo AK, Ojji DB, Adeoye MA, Ochulor KC, Oladapo OO, and Falase AO

Departments of Medicine and Haematology, University College Hospital, Ibadan, Nigeria

Medical advances in the management of patients with sickle cell disease have led to a significant increase in life expectancy. Pulmonary hypertension is emerging as one of the causes of morbidity and mortality in adults with sickle cell disease. About 2% of adult Nigerians have sickle cell anemia. The prevalence of pulmonary hypertension in Nigerian adults with sickle cell anemia is unknown. Our objective was to estimate the pulmonary artery systolic and diastolic pressures in subjects with sickle cell anemia seen at the University College Hospital, and to determine the frequency of pulmonary hypertension among them. Ninety patients (38 males and 52 females) with sickle cell anemia in steady state and comparable age and sex-matched normal controls had clinical evaluation and echocardiographic examination. They all had Doppler echocardiographic assessment of pulmonary artery pressures. The mean age of SCA subjects was 26.10±7.989 years while the mean age for the control group was 25.55±7.077 years. The sickle cell anemia subjects had lower diastolic blood pressure as well as body mass index. There was no difference in the LV systolic indices between the two groups. The SCA subjects had larger cardiac volumes compared with the control group. There were higher pulmonary systolic and diastolic pressures among SCA subjects. The frequency of pulmonary hypertension as assessed by a tricuspid regurgitant jet velocity of \>2.5 m/s in this study was 12.2%. The patients with pulmonary hypertension in this study had mild pulmonary hypertension as evidenced by the range of tricuspid regurgitant jet velocity of \<2.9 m/s. However, two of the subjects had tricuspid regurgitant jet above 2.9 m/s. The values in these SCA subjects were 2.97 m/s and 3.2 m/s, respectively. Larger left ventricular dimensions and volumes, higher stroke volume, and increased left ventricular mass indexed by body surface area, were found to be associated with pulmonary hypertension. A multivariate analysis of the potential predictors of pulmonary hypertension in this study showed that the male sex and lower PCV were independent predictors of pulmonary hypertension in SCA patients. This study has shown that the pulmonary artery systolic and diastolic pressures are higher in SCA subjects than normal controls. Higher age, male sex and low PCV have been shown in this study to be independent determinants of pulmonary arterial pressure in subjects with SCA in Nigeria.

2.26: Epidemiology of pulmonary heart disease in Nigeria: Insight from the Abeokuta Heart Failure Registry

Ogah OS, Falase AO, Stewart S, and Sliwa K

Department of Medicine, University College Hospital, Ibadan, Nigeria; Preventative Health Baker IDI Heart and Diabetes Institute Melbourne, Australia; Hatter Cardiovascular Research Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

Recent data shows that pulmonary heart disease, right heart failure or corpulmonale is becoming an important issue worldwide. This is because the disease is now more frequently diagnosed and attention is now more than ever being focused on the study of right heart function. The true epidemiology of this is disease is unknown. In the US, for example, "among 807,000 patients hospitalized with pulmonary hypertension as one of the diagnoses between 2000 and 2002, 61% were women and 24% were younger than age 65." The paucity of data is even worse in developing countries. We used the data from the Abeokuta Heart Failure Registry to describe the epidemiology of the disease in Nigeria. The Abeokuta Heart Failure Registry was used to define and characterize HF in this southern city of Nigeria. It was chosen to provide a large database that contains patients' characteristics, etiology, and modes of care, as well as outcome of patients admitted for HF. The study was conducted at the Federal Medical Centre and at the sacred Heart Hospitals in Abeokuta. Eligible subjects were those with new onset HF of decompensated chronic established HF. The Framingham criteria were used for diagnosis of HF and all cases were confirmed by echocardiography. A standardized profoma was used to collect information on demographics, medical history, symptoms, signs, investigations as well as medication and outcome of patients. Diagnosis of pulmonary hypertension was based on standard criteria. During the period of study (2006-09) a total of 41 subjects were admitted with diagnosis of right heart failure or corpulmonale. There were 23 men and 18 women, constituting 56.1% and 43.9%, respectively. The mean age was 63.3±16.3 years (range 23-90 years). The identified etiology of corpulmonale from this registry were: COPD/COAD (26,63.4%); sickle cell disease (4,9.8%); pulmonary tuberculosis (2,4.9%); connective tissue disease (2,4.9%); and primary pulmonary hypertension (2,4.9%). Others included adult congenital heart disease (2,4.9%), HIV-associated pulmonary hypertension (2,4.9%), and chest wall deformity (1,2.4%). This registry result shows that chronic obstructive pulmonary disease is the commonest cause of corpulmonale. Readmission rate was high with a 6-month mortality of 12.2%.

2.27: Pulmonary hypertension associated with sickle cell anemia: A review of epidemiology, pathophysiology and management

Ogah OS, Falase AO, Stewart S, and Sliwa K

Department of Medicine, University College Hospital, Ibadan, Nigeria; Preventative Health Baker IDI Heart and Diabetes Institute, Melbourne, Australia; Hatter Cardiovascular Research Institute, University of Cape Town, Cape Town, South Africa

About 20-25 million people live with sickle cell anemia (homozygous SCD) worldwide, with 12-15 million patients in sub-Saharan Africa. In Nigeria alone, more than 6 million people are affected by the disease. With improvement in the life expectancy in people living with sickle cell anemia, end organ complications associated with this disease, such as pulmonary hypertension, are now being frequently encountered. The purpose of the paper is to review the epidemiology and pathophysiology of pulmonary hypertension in sickle cell anemia. A Medline Search of relevant literature on the topic from 1980 to 2010 was carried out. The true incidence, prevalence and burden of pulmonary hypertension associated with sickle cell anemia are unknown, especially in environments where this disease is rampant. However, available data show that 30% of patients have pulmonary hypertension with mortality rates of 40% at 40 months. It has been shown that chronic hemolysis associated with the disease results in nitric oxide scavenging, endothelial dysfunction, and down-regulation of endothelial adhesion molecules, as well as inhibition of platelet activation. People living with sickle cell anemia are at increased risk of developing pulmonary hypertension. This complication is common and most often silent, under-recognized, and associated with increased mortality. There is need for a global registry of pulmonary hypertension in sickle cell anemia.

2.28: Markers of left and right ventricular remodeling in a native African hypertensive cohort

Ojji D, Lacerda L, Lecour S, Adeyemi Billyrose M, and Sliwa K

Departments of Medicine and Medical Laboratory Sciences, University of Abuja Teaching Hospital, Gwagwalada, Abuja; and Hatter Institute for Cardiovascular Research in Africa, University of Cape Town Medical School Campus, Cape Town, South Africa

Although hypertension affects every ethnic group, the consequences are said to be more devastating among black patients. One of the main manifestations of hypertension\'s end-organ effects, especially in black patients, is hypertensive heart disease which includes left ventricular hypertrophy (LVH), increasing vascular and ventricular stiffness and diastolic dysfunction which ultimately lead to heart failure (HF) if not adequately treated. Although brain natriuretic peptide is recognized as an indicator of the presence and severity of heart failure including hypertensive (HF) in native Africans, the diagnostic value in differentiating hypertensive LVH without HF from hypertensive HF due to systolic and/or diastolic dysfunction is unclear. Our objective necessitated a cohort study in 250 Nigerian patients to study the role of novel biomarkers as well as natriuretic peptides in this cohort. We initiated a prospective cohort study. Echocardiography was performed on all subjects. Measurements taken include left ventricular dimensions and transmitral pulse wave Doppler flow. LVH was considered present when left ventricular mass/height 2.7 exceeded 46.7 gm/m 2.7 in women and 49.2 gm/m 2.7 in men. Right ventricular (RV) systolic function was assessed on echocardiography using tricuspid annular plane systolic excursion (TAPSE) method. Plasma NT-pro-BNP was measured using electrochemiluminescence type immunoassay. Preliminary data on a subgroup of 88 patients studied will be presented: 60.2% were male, 39.8% female, and the mean age was 52.0 (10.7) years. There was no significant difference in the NT pro BNP levels between hypertensive subjects with LVH and those without. There is, however, a significant difference when the NT-pro-BNP levels of hypertensive subjects with LVH but without HF was compared with those with hypertensive HF (430.80 fmol/ml versus 582.39 fmol/ml, P=0.004). In addition, subjects with hypertensive HF have significantly worse RV systolic function compared to hypertensive subjects with LVH but without HF, with TAPSE values (23.4 mm versus 16.6 mm, P=0.000). NT-pro-BNP may be a useful biochemical marker in differentiating between hypertensive heart failure and hypertensive left ventricular wall hypertrophy without heart failure in the native African population. The contribution of RV function to progression of disease needs to be further investigated.

2.29: Serotonin passes through myoendothelial gap junctions to promote pulmonary arterial smooth muscle cell differentiation

Gairhe S, Gebb SA, and McMurty IF

Departments of Pharmacology, Cell Biology and Neuroscience, and Medicine, College of Medicine, University of South Alabama, Mobile, AL, USA

Myoendothelial gap junctional signaling mediates pulmonary arterial endothelial cell (PAEC)-induced activation of latent TGF-β and differentiation of co-cultured pulmonary arterial smooth muscle cells (PASMCs), but the nature of the signal passing from PAECs to PASMCs through the gap junctions is unknown. Because PAECs but not PASMCs synthesize serotonin, and serotonin can pass through gap junctions, we hypothesized that the monoamine is the intercellular signal. Our objective was to determine if PAEC-derived serotonin mediates myoendothelial gap junction-dependent PAEC-induced differentiation of PASMCs. Rat PAECs and PASMCs were monocultured or cocultured with (touch) or without (no-touch) direct cell-cell contact. In all cases, tryptophan hydroxylase 1 (Tph1) transcripts were expressed predominantly in PAECs . Serotonin was detected by immunostaining in both PAECs and PASMCs in PAEC:PASMC touch coculture, but was not found in PASMCs in PAEC:PASMC no-touch coculture or in PASMC:PASMC touch coculture. Furthermore, blockade of gap junctions in PAEC:PASMC touch coculture inhibited serotonin transfer from PAECs to PASMCs. Inhibition of serotonin synthesis pharmacologically or by small interfering RNAs to Tph1 in the PAECs inhibited the PAEC-induced activation of TGF-β signaling and differentiation of PASMCs. The PAEC-derived serotonin in touch cocultured PASMCs was partly colocalized with smooth muscle α-actin. Serotonin synthesized by PAECs is transferred through myoendothelial gap junctions to PASMCs, where it activates TGF-β signaling and induces differentiation. This finding suggests a novel role of intercellular serotonin signaling in PASMC differentiation, and alteration of this signaling pathway may contribute to vascular remodeling in pulmonary hypertension.

2.30: Doppler echocardiographic assessment of pulmonary artery pressure in apparently healthy Nigerian primary school children in Ibadan (Western Nigeria)

Udo PA, Orimadegun AE, Omokhodion FO

Department of Pediatrics, University of Uyo Teaching Hospital Institute of Child Health, University of Ibadan; College of Medicine, University of Ibadanth

Pulmonary hypertension is quite prevalent globally. The existing reference values for pulmonary artery systolic pressure were determined through studies in Caucasians. There is need to examine the values in Nigerian children and to encourage regular pulmonary artery pressure monitoring in the developing world. The objective of this study was to use Doppler echocardiography to assess the pulmonary artery pressure values in apparently healthy Nigerian children (in Ibadan) aged 5-12 years. Our design was a cross-sectional study. A multi-stage sampling method was used to recruit 223 apparently healthy primary school children (96 males, 127 females) aged 5-12 years from randomly selected private and public primary schools in the Ibadan North local government area of Oyo state. The pulmonary artery systolic pressure (PASP) of those that had tricuspid regurgitation was measured using echocardiography. The mean PASP (±1SD) of all the study subjects was 22.17 (5.7) mmHg with a 95% confidence interval of 21.4 -- 22.9. There was no significant difference in the values of the PASP within each socioeconomic class and among all the classes (F= 0.252, df= 4, P=0.908). There was no significant difference in the mean PASP of the subjects within each age and among all ages (F=1.640, df=7, P=0.126). There was no correlation between the mean PASP and age, weight, height, BMI, BSA in this study. There was also no statistically significant difference between the PASP of males and that of females in this study. Among the 223 apparently healthy primary school children (aged 5-12 years) in this study, the mean pulmonary artery systolic pressure (PASP) was found to be 22.17 (5.7) mmHg with a 95% confidence interval of 21.4--22.9. The values of the PASP revealed no statistically significant gender difference nor any correlation with age, weight, height, BMI or BSA. So PASP could not be predicted by any of these variables.

2.31: Adverse events of pulmonary hypertension pharmacotherapy in children

Roldan T and Cerro MJ

Department of Pharmacology, Pediatric Pulmonary Hypertension Unit, "La Paz" Children\'s Hospital, Madrid, Spain

There is limited information about adverse events of pulmonary hypertension drug therapy in the pediatric population. Our objective is to evaluate and characterize the frequency and severity of adverse events of pharmacological treatment of pulmonary hypertension (PH) in pediatric patients. The secondary objective is to identify possible risk factors for these adverse events, through an observational, retrospective, longitudinal, descriptive, single-center case series. We reviewed the medical records of pediatric patients receiving specific treatment for pulmonary hypertension (sildenafil, bosentan, iloprost, treprostinil) in our pediatric PH clinic and collected variables related to patient (gender, age, diagnosis, and WHO functional class), drug therapy variables (drug or drugs, dose, regimen and duration), and variables related to possible adverse events detected (description of the adverse effect, severity, and if it had caused modification or withdrawal of the dose). The data were processed for statistical analysis in SPSS version 11.5. We included 63 pediatric patients, 32 male (50.8%) and 31 female (49.2%). Median age at onset of treatment was 3.4 years (0.1-18). The most common etiology was congenital heart disease with 33 cases (52.4%), followed by lung disease in 8 (12.7%). Most of the patients (76%) were in an advanced functional class (III or IV) at the initiation of therapy. The drug most commonly used in monotherapy was sildenafil, (56%), followed by bosentan (23%), and the most common combination therapy was sildenafil + bosentan. More than half of the patients (34/63, 53.97%) suffered some kind of adverse events. We recorded 90 episodes with 25 different side effects. The most frequent were gastrointestinal disorders in 14 patients (22.2%) and erections in 7 boys (21.9%), followed by headaches (11.1%), respiratory complications of inhaled iloprost (11.1%), hemorrhagic diathesis (9.5%), and flushing (9.5%). Regarding the severity of adverse events detected, 46.7% (n=42) were mild, 43% (n=39) moderate, and 10% (n=9), severe. In eight cases, the treatment was suspended, and one patient needed hospital admission due to the adverse effect. In most situations (64.8%; n=59), the physician\'s decision was to continue treatment, and in 19.8% (n=18) to reduce the drug dose. Five adverse events needed pharmacological treatment: ranitidine, paracetamol and salbutamol. The presence of combined treatment was the only variable related to increased number of adverse effects that reached statistical significance (P\<0.05). We observed an increased number of side effects with increasing age and more advanced functional class, but with P\>0.05. Age also influenced the type of adverse reactions observed: cefaleas were more common in older children (13.3% to 24% in children 2-8 years, and 24% in children 8-18 years, P\<0.05). On the contrary, the incidence of gastrointestinal disorders decreased with increasing age (31.0% for children under 2 years, 33.3% in age group 2-8 years, 10% in children older than 8 years). Although more than half of patients had suffered some adverse reaction, treatment with specific drugs for PH in the pediatric population was relatively safe, showing a low rate of serious adverse events, both in monotherapy and in combination that did not need modification of the prescribed dose in most cases. Combined treatment was associated with a higher rate of adverse effects. The age of the patients influenced the type of observed adverse events: headaches were more common in older children and gastrointestinal disorders in the younger ones.

2.32: Long-term endothelin receptor antagonist therapy may predispose to carcinogenesis in patients with pulmonary arterial hypertension

Safdar Z and Qureshi H

Pulmonary-Critical Medicine, Baylor College of Medicine, Houston, TX, USA

Endothelin receptor antagonists (ETRAs) are commonly used to treat pulmonary arterial hypertension (PAH). Previous data suggested a carcinogenetic potential of ETRA in animals that were treated for an extended period with high dose ETRA. However, data on carcinogenic potential of long-term ETRA therapy has not been reported. We report our novel finding in five PAH patients who developed a malignancy while on ETRA therapy. Data review was conducted at the Baylor Pulmonary Hypertension Centre from 01/2005 to 12/2010 that identified five patients who developed a malignancy while on ETRA therapy. During this period approximately 280 PAH patients were treated with an ETRA at this center. Demographic data, NYHA/WHO functional class, six-minute walk distance (6-MWD), type of cancer, echocardiogram, and survival data were collected. The mean age of the five PAH patients was 55.4±8.6 years (Mean±SD). All were female and duration of PAH was 6.86±1.9 years. Mean duration of ETRA therapy was 4.6±0.89 years. At the time of cancer diagnosis, BNP levels were 117±114 pg/ml, 6-MWD was 398±67 meters, right ventricular systolic pressure was 83±21 mmHg, RAP was 11±2 mmHg and cardiac index was 2.4±0.3 L/min/m^2^. Follow-up duration after cancer diagnosis was 0.74±1.6 years. One patient developed bronchoalveolar lung cancer, two patients had infiltrating ductal cancer, one had malignant melanoma, and one had multiple myeloma. One patient had died while the other four patients were alive at the last follow-up. Carcinogenetic potential of ETRA should be considered in PAH patients who are on long-term ETRA therapy. Other unidentified factors may also predispose to carcinogenesis. Further studies are needed to confirm these findings.

2.33: Noninvasive evaluation of pulmonary hypertension and its correlates among adult patients with sickle cell disease

Mbakwem AC and Kehinde MO

Department of Medicine, University of Lagos, Lagos, Nigeria

Pulmonary hypertension is a relatively common complication in adult patients with sickle cell disease (SCD). Chronic hemolysis and asplenia have been identified as the pathological link between hemolytic anemia and pulmonary hypertension. There is paucity of data on the prevalence of pulmonary hypertension in SCD in our environment. We, therefore, evaluated the prevalence of pulmonary hypertension and its correlates in stable adult patients with SCD attending the sickle cell clinic in our institution. Participants were recruited from the adult sickle cell clinics of the Lagos University Teaching Hospital and were eligible if they were 18 years or older of age, had electrophoretic pattern of hemoglobin SS and were in steady state. Clinical data of the subjects were obtained. A transthoracic echo was used to for cardiac evaluation and the peak regurgitant jet velocity was used to estimate the right ventricular pressure gradient making use of the Bernoulli equation. Pulmonary systolic artery pressure was computed by adding the estimated right atrial pressure. Data for 48 subjects (20 males and 28 females) so far evaluated is presented. The mean age of the subjects was 25.85±9.61 years and this was similar for both males and females, P=0.18. The mean pulmonary artery pressure was 13.88±8.74 mmHg and the males had a higher mean pulmonary artery pressure than the females though this was not significant, 16.18±10.10 versus 12.56±7.57 mmHg, P=0.20. Pulmonary hypertension was defined as pulmonary artery pressure ≥25 mmHg, which was seen in seven (14.58%) of the subjects (four males and three females). Pearson\'s correlation was positive between the pulmonary artery pressure and age, r=0.290 P=0.05; ECG LVH by Cornell\'s criteria, r=0.305 P=0.04 and a trend with amount of blood transfusion, r=0.364, P=0.052. Pulmonary hypertension does exist in SCD patients in Nigeria with no apparent difference in gender distribution. There seems to be a relationship with age and the amount of blood transfusion patients require.

2.34: Pulmonary hypertension among patients with sickle cell disease in Africa

Wonkam A

Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé Cameroon; Division of Human Genetics, University of Cape Town, Cape Town, South Africa

In sub-Saharan Africa (SSA), sickle cell disease (SCD) occurs at its highest frequency: 5-40% sickle cell trait and up to 300,000 affected babies born each year. Patients who are homozygous for the sickle hemoglobin mutation can present with remarkably different clinical courses, varying from death in childhood to being relatively well even until old age. Abnormal transcranial Doppler velocity and pulmonary hypertension are, respectively, proxy of stroke episodes risk and cause of death of SCD patients. The etiology of pulmonary hypertension is multifactorial, including hemolysis, chronic hypoxemia, throboembolism, prenchymal and vascular injury because of sequestration of sickle enrythrocytes. Studies mostly in the US suggest a prevalence of pulmonary hypertension ranging from 20 to 40% in SCD. There is very little description of these phenotype in African SCD patients living on the African continent, where two-third of the patients live. Studies and programs that could lead to the detection and treatment that may reduce regurgitant jet velocity and potentially reverse the disease process are needed to prevent the increased morbidity and mortality associated with pulmonary hypertension in SCA.

2.35: Pulmonary hypertension and pulmonary vascular remodeling in mouse models of schistosomiasis

Crosby A

Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke\'s Hospital, Cambridge, UK

Schistosomiasis is the most common worldwide cause of pulmonary arterial hypertension (PAH) and is particularly prevalent in the developing world. Praziquantel is the drug of choice and has been shown to reverse the liver pathology associated with *Schistosoma mansoni* in mice. More than 80% of patients with PAH in the Western world have a mutation in bone morphogenetic protein type-II receptor (BMPR-II), which is a member of the transforming growth receptor-beta (TGF-b) superfamily and is important in cell proliferation and differentiation. We sought to determine whether praziquantel could reverse established pulmonary vascular remodeling and pulmonary hypertension in a mouse model of *S. mansoni* and to determine if mice with a heterozygous null mutation in BMPR-II were more susceptible to schistosomiasis-induced PAH, compared to wild-type littermates. C57/BL6 mice were infected percutaneously with a low dose of *S. mansoni*. At 17 weeks post-infection mice were either sacrificed or received praziquantel by oral gavage or a vehicle control. Right ventricular systolic pressure (RVSP) and right ventricular (RV) hypertrophy, liver and lung egg counts were measured at specified time points. Pulmonary vascular remodeling was assessed by morphometry, following immunohistochemistry. A cytokine array was performed and the degree of infectivity was measured by fecal egg counts. In a separate cohort of animals wild-type C57/BL6 mice and mice with a heterozygous null mutation in BMPR-II (mutant mice) mice were infected percutaneously with a low dose of *S. mansoni* and measurements (as above) were performed 17 weeks post-infection. In addition, human and mouse pulmonary arterial smooth muscle cells (PASMC) were cultured with *S. mansoni* eggs for 24 hours. At 24 hours the expressions of cytokines in PASMC were measured by qPCR and cytokine levels in the cell supernatant were measured by ELISA. At 25 weeks post-infection there was a significant increase in RVSP and RV hypertrophy between infected and control mice, which was reversed by praziquantel treatment. RVSP was elevated in mice at 25 weeks post-infection but had normalized with praziquantel treatment. There was a significant increase in the muscularisation of small pulmonary arteries following 25 weeks of schistosomal infection, which was prevented by with praziquantel treatment. Liver, lung and fecal egg counts were elevated following 25 weeks of schistosomal infection and substantially reduced with praziquantel treatment. At 17 weeks post-infection there was no significant difference in RVSP, the degree of RV hypertrophy, liver weight or body weight between wild-type or BMPR-II mutant mice. However, 33% of the mutant mice died prematurely. After 24 hours co-culture with eggs both mouse and human PASMC showed an increase in cytokine expression and cytokine release. More specifically we saw an increase in IL-6, Kc (mouse homologue of IL-8) and IL-13 expression and an increase in IL-6 and Kc secretion. We also saw an increase in PASMC proliferation, determined by Ki67. There was a suggestion that PASMC from mutant mice may display an increase in cytokine response to egg stimulation. These studies have shown that severe pulmonary vascular remodeling accompanied by an increase in RVSP and RV hypertrophy occurred 25 weeks post-infection in a mouse model of *S. mansoni* infection. Importantly, this study has shown that progression of disease can be prevented by two oral doses of praziquantel. The mechanism thought to underlie the dramatic pulmonary vascular remodeling is a local increase in inflammatory cytokines. In addition we have shown that a heterozygous null mutation in BMPR-II does not predispose to schistosomiasis-induced PAH. We have also shown that PASMC respond to *S. mansoni* eggs by an increase in gene expression and release of inflammatory cytokines. These may play a part in inducing pulmonary vascular remodeling by stimulating PASMC proliferation. However, this affect was not significantly enhanced by BMPR-II mutations.

2.36: Subcellular mechanisms in IPAH: Coordinate dysfunctions of the Golgi-ER-mitochondrial axis

Sehgal PB

Departments of Cell Biology & Anatomy, and Medicine, New York Medical College, New York, New York USA

In 1977 Smith and Heath reported observing using electron microscopy (EM), the marked cystic dilatation of the endoplasmic reticulum (ER) in PAECs in hypoxic rats with PAH. In 1979, Smith and Heath reported observing, also using EM methods, dilatation of the ER cisternae in cells in vascular lesions of PAH in man. These seminal observations on the subcellular mechanisms in the pathogenesis of PAH have gone largely unnoticed until now. In recent years, we have reported Golgi apparatus enlargement and fragmentation, increased cytoplasmic dispersal of the Golgi tether giantin, and defects in intracellular trafficking leading to global changes in the cell surface landscape of pulmonary vascular cells within PAH lesions. Increased cellular levels of an ER structural protein RTN4/Nogo-B have been reported in endothelial and smooth muscle cells in pulmonary vascular lesions in idiopathic PAH as well as the inability of RTN4^-/-^ mice to develop PAH in response to chronic hypoxia. Other investigators have implicated mitochondrial dysfunction in the pathogenesis of IPAH. In observations that unite data concerning Golgi, ER and mitochondrial dysfunctions into a coordinated pathophysiology in this disease, we demonstrated that knockdown of a particular estrogen- and progesterone-responsive STAT protein species in the cytoplasm of HPAECs and HPASMCs leads to Golgi enlargement and fragmentation, cystic dilatation of ER, reduced intracellular trafficking in synergy with knockdown of BMPRII (equivalent to BMPRII haploinsufficiency), and increased mitochondrial fragmentation with reduced TMRE uptake---all changes that we and others have shown to occur in IPAH. Overexpression of an ER-associated GTPase blocks these changes. The data, in principle, provide new insights into potential second-hit, low-penetrance and sexual dimorphism effects in PAH and suggest new avenues of gene therapy aimed at correcting the subcellular defects first observed in PAH by Smith and Heath in 1977-1979.

2.37: The behavior of the right ventricular dysfunction by echocardiography and clinical transthoracic

Murillo C

Unidad Estratégica de Bioprospección, Instituto Nacional de Biodiversidad Santo Domingo de Heredia, Costa Rica

The purpose of this study was to describe the behavior of the right ventricular dysfunction by echocardiography and clinical transthoracic (ECTT). It is a non-invasive procedure with high availability, and is rapid, sensitive and reliable. Thromboembolic pulmonary hypertension disease (CTEPH) is a clinical entity characterized by an increase in pulmonary arterial pressure secondary to the presence of thrombi intraluminal organized fibrous stenosis and even obliteration of the pulmonary arteries, which result in the elevation of the pulmonary vascular resistance and changes in the right heart, by pressure overload. CTEPH was long considered a very rare entity. Only 0.5-1% of the EP performed the event, but now its incidence has increased to 3.8%. We studied 10 CTEPH patients diagnosed with admission to the service Cardioneumologia in the months March to December 2009. The diagnosis was established according to the ACC and AHA consensus with the following studies: (V/Q scan), computed tomographic pulmonary disease, and prior ECTT PSAP with a report greater than 40 mmHg. All of them were narrowing the demographic variables, risk factors, 6-minute walk, 12-lead ECG Doppler flow shunts and RV ECTT. The variables were obtained from subjects in stable condition. Here, "stable condition" was defined as at least 1 month without manifestations. We studied 10 patients, 6 men and 4 women, with an average age of 45-51 years. It was observed that most patients were overweight (BMI 25.1 to 29.9 kg/m^2^). Risk factors related to venous thromboembolic disease were smoking, exposure to wood smoke, and antiphospholipid antibody syndrome (SAF). The only acquired and inherited thrombophilias reported were SAF. During the 6-minutes walk test the clinical manifestations were small (only dyspnea), but the impact on physiological variables was obvious. For the most part the results of laboratory tests were within normal parameters. However, the rise in the numbers of the distribution width erythrocyte (ADE), uric acid, the pro-natriuretic peptide *N*-terminal (NT pro-BNP), the total bilirubin and times coagulation was interesting, as anticoagulant therapy found seven patients with coumarin, and two patients with unfractionated heparin. The glucose was found in the upper normal limit, while the ratio of indirect and total bilirubin was found decreased. In the surface electrocardiogram only found in more than 50% of the shows, 4 of 11 criteria to demonstrate ventricular enlargement right, being the 2 most representative QRS axis \>110 degrees and the sum of the R wave in V1 and the S wave in V5 \>10 mm. By echocardiography transthoracic feature: severe pulmonary hypertension, increased right ventricular diastolic diameter and increased thickness of the right ventricular free wall was also found a TAPSE, a fraction and right ventricular Tei index increased. By applying the technique of tissue Doppler velocities we obtained minor contraction in the right ventricular free wall, as in the interventricular septum at the middle segment, and a delay in the interventricular septum contraction with respect to the free-wall VD. The chronic pulmonary embolism produces severe pulmonary arterial hypertension. Pulmonary arterial hypertension causes geometric changes in right ventricular anatomy. The alterations in venous return produced right ventricular dysfunction. The surface ECG is an insensitive method for assessing right ventricular enlargement. ECTT markers with greater sensitivity for the detection of right ventricular dysfunction include the TAPSE and Tei index. The tissue Doppler ultrasound best assessed right ventricular deterioration, and that allows assessment of contractile motility flows and SIV and free-wall VD.

2.38: Single and combination therapy with erythropoietin and sildenafil on hypoxia-induced PAH

Østergaard, L

Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense M, Denmark

Pulmonary arterial hypertension (PAH) is a group of diseases characterized by elevated pulmonary pressure. This can lead to right ventricular hypertrophy and if left untreated, patients might die from right heart failure within an average of 3 years. The present study was designed to investigate single and combination therapy with erythropoietin (EPO) and sildenafil on hypoxia-induced PAH. Mice were randomized, first in a normoxic and a hypoxic group and second to receive saline, EPO, sildenafil or EPO and sildenafil. EPO was injected three times per week (500 IU/kg) and sildenafil daily (1 mg/kg). The animals were exposed to 3 weeks of either hypoxia (10% oxygen) or normoxia, after which they underwent the different treatments for an additional 2 weeks under the same conditions. Immunohistochemistry was performed to elucidate changes in pulmonary morphology and of right heart hypertrophy. Plasma levels of cardiotrophin-1 and atrial natriuretic peptide (ANP) were measured as well as ventilatory parameters using whole body plethysmography. The pulmonary pressure was measured using right heart catheterization. The increase in pulmonary pressure after hypoxic exposure was attenuated by either drug alone but significantly more by the combination treatment. The hypoxia-induced increase in right ventricular hypertrophy and medial wall thickness of pulmonary arterioles was significantly reduced with the combination therapy compared both to the control and to the single treatment groups. Similar results were also observed for cardiotrophin-1 and ANP levels. Animals in the hypoxic group exhibited a deteriorated lung function that could be improved upon treatment. The combination treatment with EPO and sildenafil demonstrated an improvement in the clinical outcome in hypoxia-induced PAH in rodents, superior to that observed for either drug given alone.

2.39: A practicable risk score for pulmonary hypertension

Tiede H, Felix J, Wilkins M, Steyerberg E, Seeger W, Grimminger F, and Ghofrani A

University of Giessen Lung Center, Giessen, Germany; Erasmus University of Rotterdam, The Netherlands; Imperial College London, London, UK

Several markers that are associated with severity and/or prognosis of disease have been suggested for patients with pulmonary arterial hypertension. We aimed to assess the utility and validity of a new prognostic score for different forms of pulmonary hypertension based on comprehensive databases from the PH centers Giessen and Imperial College in London. Every consecutive patient undergoing right heart catheterization with proven pulmonary hypertension was included in the Giessen registry from 1994 to 2011. Overall 1-, 3-, and 5-year survival rates were 89.9, 76.1and 65.6% respectively. Of the total, 615 patients (35.7%) had PAH, 439 (25.4%) had pulmonary hypertension due to chronic lung diseases (PH-LD, mainly interstitial lung disease and chronic obstructive lung disease), 419 (24.3%) had chronic thromboembolic pulmonary hypertension (CTEPH), 224 (13%) had pulmonary venous hypertension, and 28 (1.6%) had pulmonary hypertension due miscellaneous or unknown causes. Differences in survival between the etiological groups were highly significant (P\<0.001), with 1-, 3-, and 5-year survival rates of 89.8, 78.1 and 67.2% respectively in PAH opposed to 86.6, 65.4, and 53.7% respectively, in PH-LD. In multivariate analysis, uric acid, urea, leucocyte count, brain natriuretic peptide, heart rate, sodium, 6-minute walk test distance, oxygen saturation during 6-minute walk test, cardiac output and systolic blood pressure at baseline were significantly associated with survival. We built a prediction model for all classes of PH with outcome being death from any cause. The equation was validated with the cohort from Imperial College, London, UK. By integration of different predictors in one prognostic model we took the complex pathophysiology of PH into account. A formula has been generated that may help researchers and clinicians to better anticipate the prognosis of an individual patient irrespective of the underlying cause of pulmonary hypertension.

2.40: Use of combination therapy in postoperative persistent pulmonary arterial hypertension in children

Kulkarni S, Jadhav M, Garekar S, and Rao S

Children\'s Heart Center, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

We examined the use of combination therapy in six patients with persistent pulmonary arterial hypertension (PAH) after corrective surgery for congenital heart defects. Combination of sildenafil and bosentan was used in six patients for persistent pulmonary arterial hypertension (PAH) after corrective surgery for congenital heart defects. Out of these six patients, four had persistent PAH crisis in the immediate postoperative period and needed inhaled nitric oxide. Combination of sildenafil and bosentan was used in six patients for persistent PAH after corrective surgery for congenital heart defects. Out of these six patients, four had persistent PAH crisis in the immediate postoperative period and needed inhaled nitric oxide. Pulmonary artery pressures remained very high after discontinuation of nitric oxide after 48 hours and they could not be extubated. These patients were given combination of sildenafil and bosentan while coming off from nitric oxide and then they could be extubated safely. The other two patients had persistently high pulmonary arterial pressures after surgery at the time of discharge. They were initially started only on sildenafil with marginal improvement in pulmonary arterial pressures. The addition of bosentan helped with a significant reduction in pulmonary arterial pressures at 6 months follow-up. Combination therapy of sildenafil and bosentan helps create a significant reduction in pulmonary arterial pressures in immediate postoperative period. It can be used effectively on follow-ups if pulmonary artery pressures remain elevated after surgeries for congenital heart defects.

2.41: LC/MS/MS method for simultaneous analysis of arachidonic acid and its endogenous eicosanoid metabolites and prostaglandins in rodent lung tissue

Sagliani K, Hill NS, Fanburg BF, Dolnikowski G, Levy BL, and Preston IR

Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA, USA; Human Nutrition Research Center of Aging, Boston, MA, USA; Brigham and Women Hospital, Boston, MA, USA

Lipoxygenase (LOX)- and cycloxygenase (COX)- generated lipid mediators are biomarkers of inflammation, cell proliferation, and oxidative stress and possess biological activity in various disease states, including those affecting the pulmonary vasculature. Therefore, their quantification may be important in understanding the pathophysiology of pulmonary hypertension, in which oxidative stress via lipid metabolites plays a role. Liquid chromatography with tandem mass spectrometer detection (LC/MS/MS) methods allow a highly selective, sensitive analysis of bioactive lipids. However, the LC/MS/MS methods currently used do not allow for simultaneous separation of the major eicosanoids and prostaglandins without multiple high performance liquid chromatography (HPLC) separations. We developed a LC/MS/MS method which allows for simultaneous separation and quantification of the major lipid mediators in healthy rat and mouse lung. The method was validated by analyzing multiple times same samples. Lungs were homogenized, the homogenates were centrifuged at 4,500 rpm for 30 minutes at 4°C. The diluted supernatant was acidified on ice to a pH of 4.0 with 1-N HCl. A 20-μL aliquot of internal standard master mix (15, 12, 5, HETE-d8, PGE2-d4, TBX2-d4) was added to each sample. From each sample, 100 μL were used to determine protein concentration using the Bradford assay. For the HPLC separation of arachadonic acid metabolites, we used a Luna-3-μm, phenyl-hexyl, 2×150-mm analytical column. The Agilent 1200 Series HPLC system consisted of a high-performance binary pump, and a 108-well plate autosampler at 4°C, and column compartment was set at 25°C. Targeted profiling of eicosanoids and prostaglandins was performed using a 5500 QTRAP (ABSciex) hybrid triple quadrupole linear ion trap mass spectrometer equipped with a turbo ion-spray electrospray ionization (ESI) source. The dwell time used for all experiments was 80 msec. The source-dependent MS parameters such as temperature and ion-spray voltage were set at 400°C and -4,500 v, respectively. Results were reported in pg/μg protein as mean±STD. T-test was used to compare the results between species and P\<0.05 was considered significant. Extraction coefficient was 75%. There is significant interspecies difference in the values of: 12-HETE, 8-HETE, PGE2, PGI2 and the ratio of PGI2/TBX2. We found significant differences in the normal levels of various arachidonic acid metabolites. This can account for difference in responses to stimuli which cause pulmonary hypertension, such as hypoxia and monocrotaline. This study is the first to report a sensitive, specific, robust and validated LC/MS/MS method that allows simultaneous analysis of arachidonic acid metabolites and can be used in the future to study various disease states such as pulmonary hypertension.

2.42: Determination of endogenous bioactive lipid profile in experimental pulmonary hypertension

Sagliani K, Hill NS, Fanburg BF, Warburton RW, Dolnikowski G, Levy BL, and Preston IR

Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA, USA; Human Nutrition Research Center of Aging, Boston, MA, USA; Brigham and Women Hospital, Boston, MA, USA

Lipoxygenase (LOX)- and cycloxygenase arachidonate products, including prostaglandins (PGs) and hydroxyeicosatetraenoic acids (HETEs) are known to modulate inflammation within tissues. The role of inflammation and increased oxidative stress in pulmonary hypertension has been recently acknowledged. The importance of lipid mediators in modulating inflammation, cell proliferation and migration, and pulmonary vascular remodeling is highlighted by the use of prostaglandin modulators as treatment options (prostacyclin replacement therapy). We showed previously that in experimental model of hypoxia-induced pulmonary hypertension there is an upregulation of the 12-lipoxygenase and its product 12-HETE stimulates pulmonary artery smooth muscle cell proliferation. Here, we aimed to establish whether there was an imbalance of arachidonic acid products in the lungs of hypoxic rats compared with their normoxic controls and to identify those byproducts that might explain the remodeling and inflammation associated with experimental pulmonary hypertension. Rats were exposed to 2 weeks of hypoxia (11% O~2~). Normoxic controls were kept in similar conditions, but in room air. Rats with chronic hypoxia and their respective controls underwent right ventricular pressure measurements. Right ventricle/left ventricle+septum were indicators of right ventricular hypertrophy. Lungs were frozen in liquid nitrogen and were subjected to LC/MS/MS method for simultaneous determination of arachidonic acid products. Results were reported in pg/μg protein as mean±STD. T-test was used to compare the results between conditions and P\<0.05 was considered significant. Rats kept in chronic hypoxia developed elevated RV pressures and RV hypertrophy, compared with their normoxic controls. There was wide variation among levels of different eicosanoids, PGE2 and PGI2 between normoxic and hypoxic lungs. Lungs from hypoxic animals had significantly elevated levels of thromboxane 2 (TBX~2~) and the PGI~2~/TBX~2~ ratio was significantly decreased in these animals. Chronic hypoxia-induced pulmonary hypertension is associated with a local imbalance favoring the vasoconstrictor and pro-thrombotic product TBX~2~ over the vasodilator PGI~2~. This is consistent with findings described in patients with pulmonary arterial hypertension.

2.43: Lipidomic analysis of plasma from patients with pulmonary arterial hypertension: Determination of circulating arachidonic acid metabolites

Sagliani K, Preston IR, Roberts KR, Fanburg BF, Dolnikowski G, Levy BL, and Hill NS

Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA, USA; Human Nutrition Research Center of Aging, Boston, MA, USA; Brigham and Women Hospital, Boston, MA, USA

Prior reports suggest that lungs of patients with pulmonary arterial hypertension (PAH) are under oxidative stress and that bioactive lipid components derived from arachidonic acid are released and may participate in the remodeling of the pulmonary vasculature. In addition, urinary metabolites of prostacyclin (PGI2) and thromboxane (TBX2), and their ratio, are abnormal in these patients, suggesting an imbalance among various products of arachidonic acid, with preference for vasoconstrictor and prothrombotic molecules. We aimed to screen plasma of PAH patients for arachidonic acid products and determine their bioactive lipid profile. We obtained plasma from consecutive patients with idiopathic or connective tissue associated PAH (WHO Group I) at the time of their right heart catheterization. Patients were grouped into treatment-naïve and those on PAH-specific therapies. Plasma from normal controls was obtained for comparison. Samples were frozen in -80°C until measurements were performed using an LC/MS/MS method. We enrolled 34 patients with PAH and 5 controls. Patients were on average 62±12 years of age, and 21 of them were females. Their WHO functional class at the time of collection was 2.7±0.8. PAH-specific therapies included: endothelin receptor blockers, PDE5 inhibitors, prostacyclins, and any combination of them. Significant differences were between controls and IPAH-treatment naïve and between IPAH-treatment naïve and IPAH-treated groups with respect to: 5-HETE, 12-HETE, 8-HETE. Levels were higher in non-treated patients and were lowered in the presence of treatment. TBX2 levels were significantly higher in IPAH-treatment naïve patients compared with controls (P=0.0049) . We established for the first time significant differences in levels of bioactive lipids in patients with two forms of PAH and their changes with treatment. Further research remains to determine the value of these changes.

2.44: Is bronchus-associated lymphoid tissue readily evident in lung sections from patients with PAH and in rates with monocrotaline-induced PH?

Yeager M

Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado USA

Pulmonary hypertension (PH) is characterized by inflammatory cell recruitment and altered pro-inflammatory cytokine profiles. In addition, anti-endothelial cell and fibroblast antibodies have been detected in the sera of patients with PAH. The possibility that an autoimmune program may be operational in these patients has been considered for nearly 30 years. In humans, bronchus-associated lymphoid tissue (BALT) plays important roles in antigen sampling and maintenance of self-tolerance during episodes of infection and chronic inflammation. We reasoned that BALT would be readily evident in lung sections from patients with PAH, and in rats with monocrotaline-induced PH. Using immunohistology, we found increased numbers of BALT that were larger in PH rats compared to controls. We found OX-62+ dendritic cells in and around BALT, which were characterized by a CD3+ T cell mantle over a follicular core of B220+ B cells coexpressing the class-switching enzyme AID. Anti-rat IgG antibodies decorated cells in BALT, adventitial compartments in large vessels, and in all three layers of medium- to small-sized vessels in lung sections from control rats. Finally, BALTs in monocrotaline-treated rats were highly vascularized by Aquaporin-1+ high endothelial venules and LYVE-1+ lymphatics. These results support the idea that chronic inflammation in PH may lead to loss of self-tolerance and autoimmunity.

2.45: Echocardiographic prediction of pulmonary vascular resistance

Opotowsky AR, Clair M, Landzberg MJ, Waxman AB, Arkles JS, Rogers F, Prasanna V, Moko L, Maron B, Fields A, and Forfia PR

Department of Medicine, University of Pennsylvania, Philadelphia, PA, Department of Cardiology, Children\'s Hospital Boston, Boston, MA, Department of Medicine, Brigham and Women\'s Hospital, Boston, MA, USA

Pulmonary hypertension is defined by elevated pulmonary artery pressure, but is comprised of a heterogeneous collection of diagnoses with distinct hemodynamic pathophysiology. Identifying patients with elevated pulmonary vascular resistance (PVR), in contrast to those with normal PVR and elevated left-sided filling pressure, is critical for appropriate treatment. We reviewed hemodynamics, echocardiography, and clinical data for 175 patients seen at a referral PH clinic who underwent echocardiography and right-heart catheterization within 1 year of each other. We derived three equations to predict PVR with echocardiography using the ratio of estimated PA systolic pressure (PASP) to RVOT VTI as a basic model, with consideration of additional terms (e.g., RVOT Doppler notching, acceleration time) that may independently predict increased PVR, as well as predictors of left atrial pressure (LAP) in more complex models. We compared these models to a published model based on the ratio of trans-tricuspid flow velocity (TTFV) to RVOT VTI:
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PASP was estimated using the simplified Bernoulli equation (P*ASP*=4×*TTFV*^2^). For AP LA dimension \<3.2 cm, est. LAP=10, if 3.2-4.2 cm then LAP=15, and if \>4.2 cm then LAP=20.

Average mean PAP was 45.3±11.9, mean PVR was 7.3±5.0 and mean PAWP was 14.8±8.1. PAWP was \>15 mmHg in 41.7% and 80% had PVR \>3WU. The published PVR prediction model systematically underestimated true PVR, especially at higher levels of PVR. There was no such systematic bias in any of the derived models, and the prediction 95% CI was narrower for all models compared with the published equation. The comprehensive equation had the greatest discriminatory power for elevated PVR\>3WU (AUC 0.914), though all models had reasonably high AUC. The sensitivities of predicted PVR\>3WU for catheterization derived PVR\>3WU for Models 1 through 4 respectively were 65.7, 95.0, 95, and 95.7%, with specificities of 91.4, 28.6, 62.9, and 45.7%. For Model 1, a cut-off predicted PVR of 1.72 corresponded to sensitivity of 95.7% and specificity of only 20%. A previously published echo model to predict PVR systemically underestimated PVR in a PH-referral population. Using a quadratic term to reflect the exponential relationship of pressure to flow improved agreement between predicted and true PVR, adding a term to account for RVOT VTI notching further improved test characteristics. While including a crude estimate of left atrial pressure provided modest additional value, this may be outweighed by increased complexity.

2.46: The use of cardiac MRI in understanding PAH in complex CHD: Case reports

Kappanayil M

Pediatric Cardiology, Amrita Institute of Medical Sciences, Kerala, India

Cardiac magnetic resonance (CMR) is emerging as a powerful tool in the assessment of congenital heart diseases, and is especially invaluable in assessing older/grown-up patients with complex structural heart diseases. CMR provides not just detailed anatomical information, but also unique physiological insight. The developing world in particular has a large burden of patients with complex heart diseases which are either unoperated, or partially palliated, or growing up with sequelae that include PAH. Many complex lesions are particularly difficult to evaluate using the conventional modalities of echocardiography and cardiac catheterization, owing to complex anatomy and/or physiology. We illustrated three case examples with CHD-PAH where MR imaging helped in the primary detailed diagnosis, as well as physiology. My object was to illustrate the usefulness of cardiac MRI in understanding PAH in complex CHD, through three case examples. Case 1: An 18-year-old girl, suspected to have complex CHD in early childhood. Social/financial limitations prevented detailed evaluation until recently. She complained of effort intolerance, NYHA class II, and had an SPO~2~ of 92%. Gadolinium-enhanced angiography showed pulmonary atresia with a large MAPCA from proximal descending thoracic aorta with an unobstructed, large connection to left lung and a proximally stenotic connection to right lung. Gadolinium-enhanced 3D angiography showed clear evidence of differential vascularity, with the left lung showing peripheral pruning, and the right lung showing rich arborization. Phase-contrast sequences were used to study the flows in the aorta, the MAPCAs to right and left lung, and the pulmonary venous returns from either lung. They showed a Qp/Qs of nearly 2:1. However, nearly 80% of the blood flow was to the normally arborized right lung (7.5 L/min), and only 20% o the left (2 L/min). The flow/time curves showed early peaking, lower peak velocity, and rapidly descending flow patterns (suggestive of PAH) in the left lung blood flows. CMR not only helped in establishing the diagnosis, but also in understanding the nature of PAH, which in this case was an Eisenmegerized left lung with a nearly normal right lung. Case 2: A 16-year-old girl with mild effort intolerance, SPO~2~ 85%, with uncertain diagnosis on previous evaluations (possibly truncus arteriosus). CMRI revealed an anatomical diagnosis of large conoventricular VSD with aortic atresia, hypoplastic ascending aorta, two balanced ventricles, large pulmonary artery overriding the VSD, dilated bilateral branch pulmonary arteries, patent ductus arteriosus shunting right-to-left and sustaining systemic blood flow, juxta ductal coarctation. Gadolinium-enhanced 3D angiography revealed reduced arborization and peripheral pruning of bilateral lungs, more prominent in the left lung. This angiographic finding was supported by phase contrast (flow) studies which showed lower flows in the left lung compared to the right, with flow/time graphs clearly suggestive of PAH. Qp:Qs (derived through flow studies) was nearly 2:1. Operability debatable---most likely Eisenmenger syndrome. Case 3: A 30-year-old Ethiopian male patient presented with features of biventricular failure and PAH, with upper body hypertension, differential cyanosis and differential clubbing. CMRI established a diagnosis of large PDA shunting bidirectional with a tight preductal coarctation of aorta, with severe biventricular dysfunction. Gadolinium-enhanced 3D angiography showed a differential vascularity pattern with peripheral pruning of the right lung vasculature. Flow/time graphs showed a pattern of PAH in both lungs, with lower flows in the right lung, with Qp:Qs of 0.9:1. Flow studies of the PDA showed a systolic right-to-left shunt and a pan-diastolic left-to-right shunt, suggesting subsystemic diastolic pressures in the pulmonary arteries (net flow being about 0.3L/min right-to-left). This patient is being currently planned for dilatation/stenting of the coarctation and subsequent hemodynamic re-evaluation for suitability for PDA closure. All the above cases reveal the usefulness of CMR in evaluating and understanding complex CHDs associated with PAH, and thereby in planning management.

2.47: Therapeutic potential of HDAC inhibitors in pulmonary hypertension

Zhao L, Chen CN, Hajji, Oliver E, Huang TJ, Wang D, Li M, McKinsey T, Stenmark KR, and Wilkins MR

Centre for Pharmacology and Therapeutics, Imperial College London, UK; Hammersmith Hospital, London, UK; Department of Pediatrics, University of Colorado Denver, Denver, CO, USA

Pulmonary arterial hypertension (PAH) is characterized by structural remodeling of pulmonary arteries and arterioles, the result, at least in part, of excessive cell proliferation and resistance to cell death. Epigenetic programming, dynamically regulated by histone acetylation, is an important mechanism for controlling cell proliferation and survival. Little is known regarding the contribution of changes in histone deacetylase (HDAC) activity to the changes in cell phenotype that occur during remodeling and overall to the development of PAH. HDAC protein expression levels were measured by Western blotting. Specifically, HDAC1 and HDAC5 levels were increased in lungs from IPAH patients and in the lungs and right ventricles of rats exposed to hypoxia. Both valproic acid (VPA), a HDAC1 inhibitor, and suberoylanilide hydroxamic acid (SAHA), an inhibitor of class I and II a/b HDACs, mitigated the development and reduced established hypoxia-induced pulmonary hypertension in the rat. Both VPA and SAHA inhibited the "imprinted" highly proliferative phenotype of fibroblasts and "R" cells from pulmonary hypertensive bovine vessels and also inhibited PDGF-stimulated growth of human vascular smooth muscle cells in culture. Exposure to VPA and SAHA was associated with increased levels of p21and FOXO3 and reduced expression of Bcl-2 and surviving. VPA also increased lung expression of BMPR2 and reduced HIF1α levels in rats exposed to hypoxia in vivo. Increased HDAC activity contributes to the vascular pathology of pulmonary hypertension. HDAC inhibitors, VPA and SAHA, may have therapeutic potential in PAH.

2.48: Atrial flutter and atrial fibrillation in patients with chronic pulmonary hypertension

Olsson KM, Nickel N, Tongers J, and Hoeper MM

Departments of Respiratory Medicine and Cardioloy, Hannover Medical School, Hannover, Germany

Supraventricular tachyarrhythmias (SVTs), especially atrial flutter and atrial fibrillation, are observed with increasing frequency in patients with pulmonary hypertension, but their clinical consequences have not been systematically evaluated. We sought to determine the prevalence and clinical relevance of these SVTs in patients with pulmonary hypertension. In a 5-year, prospective study, we analyzed the occurrence of SVTs in patients with newly diagnosed pulmonary arterial hypertension (PAH) or nonoperable chronic thromboembolic pulmonary hypertension (CTEPH). The enrolment period was 4 years, followed by a minimum 1-year follow-up. We assessed the incidence of SVTs as well as their clinical implications, treatment modalities, risk factors and impact on outcome. We enrolled 239 patients, 82 with inoperable CTEPH and 157 with PAH. At baseline, the mean 6-minute walk distance was 335 (IQR, 292-429) m. and the mean PVR at baseline was 734 (IQR, 472-922) dyn.s.cm^-5^. SVTs of new onset were detected in 48/239 (20%) patients, yielding an annual incidence of 4%. Atrial fibrillation and atrial flutter occurred with equal frequency. According to univariate Cox regression analyses, higher values of mean pulmonary artery pressure (HR 1.03, 95% CI 1.01-1.06, P=0.002), right atrial pressure (HR 1.07, 95% CI 1.05-1.16, P=0.01), and serum bilirubin (HR 1.05, 95% CI 1.02-1.08, P=0.01) as well as a lower cardiac output (HR 1.9, 95% CI 1.1-3.5, P=0.048) were linked to an increased risk of SVTs. The development of atrial fibrillation or atrial flutter resulted in deteriorations in exercise capacity, functional class and NT-proBNP serum levels. Most patients required hospitalization. A stable sinus rhythm was successfully restored in 21/24 (88%) of patients with atrial flutter and in 16/24 (67%) of patients with atrial fibrillation. Patients in whom sinus rhythm was restored had a significantly better survival than patients with persistent SVTs (P=0.01 by log rank analysis). New onset SVTs were observed with an incidence of 4% in patients with pulmonary hypertension and the risk was particularly high in patients with severe hemodynamic impairment. The development of SVTs resulted in impaired exercise capacity, clinical deterioration, and a worsened survival, particularly when sinus rhythm was not restored.
